

CURRICULUM VITAE
Kenneth Kaushansky, M.D.
August 2017

Senior Vice President, Health Sciences
Dean, School of Medicine
Stony Brook University

Education

B.S., University of California at Los Angeles	1975
M.D., University of California at Los Angeles	1979

Postgraduate Training

Internship, Department of Internal Medicine University of Washington, Seattle, Washington	1979-1980
Residency, Department of Internal Medicine University of Washington, Seattle, Washington	1980-1982
Chief Resident, Department of Internal Medicine Swedish Hospital and Medical Center, Seattle, Washington	1982
Fellowship, Division of Hematology, Department of Medicine University of Washington, Seattle, Washington	1982-1986

Professional Positions

Acting Instructor in Medicine, Department of Medicine University of Washington, Seattle, Washington	1986-1987
Assistant Professor of Medicine, Department of Medicine University of Washington, Seattle, Washington	1987-1991
Associate Professor of Medicine, Department of Medicine University of Washington, Seattle, Washington	1991-1995
Associate Director of the Program in Molecular Medicine University of Washington, Seattle, Washington	1991-1995
Professor of Medicine, Department of Medicine University of Washington, Seattle, Washington	1995-2002
Adjunct Professor of Biochemistry University of Washington, Seattle, Washington	1995-2002
Section Head, Division of Hematology, University of Washington Medical Center	1999-2002
Professor of Medicine, Department of Medicine, University of California, San Diego	2002-2010

Chairman and Helen M. Ranney Professor, Department of Medicine, University of California, San Diego	2002-2010
Distinguished Professor, Department of Medicine, University of California, San Diego	2008-2010
Professor, Department of Medicine, State University of New York, Stony Brook	2010-present
Senior Vice President for Health Sciences and Dean, School of Medicine, State University of New York, Stony Brook	2010-present

Hospital Positions Held

Attending Physician University of Washington Medical Center	1986-2002
Harborview Medical Center	1987-1994
University of California, San Diego Medical Center	2002-2010
State University of New York, Stony Brook	2010-present
Medical Staff Executive Committee, UCSD Medical Center	2002-2010
Attending Physician, Stony Brook University Hospital	2010-
Medical Staff Executive Committee, SBUH	2010-

Honors and Awards

Phi Beta Kappa	1975
Summa Cum Laude	1975
Alpha Omega Alpha	1978
Sandoz Award	1979
NIH Physician Scientist Award	1984-1989
Junior Faculty Award, American Cancer Society	1989-1992
Elected Member, American Society for Clinical Investigation	1993
Elected Member, Western Society for Clinical Investigation	1994
Elected Member, Western Association of Physicians	1995
Dameshek Award, American Society of Hematology	1996
Outstanding Investigator Award, American Federation for Medical Research	1997
Elected Member, Association of American Physicians	1998
Elected Vice-President, President-Elect, President American Society for Clinical Investigation	2001-2004
Elected, America's Top Doctors	2003-2009
Elected, San Diego's Best Doctors – Internal Medicine	2003
Elected Member, National Academy (formerly Institute) of Medicine	2004-
Elected, Vice President, President-Elect, President, American Society of Hematology	2006-2008
Elected, Fellow American College of Physicians	2006-
Elected Member, American Academy of Arts and Sciences	2006-
Elected, Master American College of Physicians	2007-
Elected, San Diego's Best Doctors – Hematology	2008

Ernest Beutler Award, American Society of Hematology	2013
Elected SUNY Distinguished Professor	2014-

Board Certification

American Board of Internal Medicine	1983
American Board of Internal Medicine, Hematology	1985

Medical Licensure

State of New York

Other Organizations

American Society of Hematology
 American Federation for Medical Research
 American Society for Clinical Investigation
 American Association of Physicians
 Western Society for Clinical Investigation
 Western Association of Physicians
 Institute of Medicine, National Academy of Sciences
 American College of Physician
 American Academy of Arts and Sciences
 Greater New York Hospital Association

Editorial Responsibilities

Member of Editorial Board, <i>Blood</i>	1992-1997
Associate Editor, <i>Blood</i>	1996-1997
Editor-in-Chief, <i>Blood</i>	1997-2002
Editorial Board, <i>The Hematologist</i>	2003-2006
Ad Hoc Reviewer for <i>Blood, Science, PNAS, J Clin Invest, Nature, J Immunol, NEJM, Biochemistry, JBC</i>	1986-
Academic Internal Medicine Insight Editorial Board	2005-2009
Williams Hematology, Associate Editor, 7 th edition	2003-2008
Williams Hematology, Lead Editor, 8 th edition	2009-2013
Williams Hematology, Lead Editor, 9 th edition	2013-2015
Williams Hematology, Lead Editor, 10 th edition	2016-
Williams Hemostasis and Thrombosis	2017-

Special National/Regional Responsibilities

Member of NIH Hematology Study Section I, Clark Lum, Chairman	1992-1996
Member of Education Committee, American Society of Hematology	1992-1996
Chairman, Education Committee, American Society of Hematology	1994-1996
Chairman, Scientific Subcommittee on Platelets and Megakaryocytes, American Society of Hematology	1993-1994
Director, Education Program of the Annual American Society of Hematology Meeting	1994-1995
Director, Scientific Program of the Annual American Society of Hematology Meeting	1995-1996

Secretary/Treasurer of Western Society for Clinical Investigation	1994-1997
President, Western Society for Clinical Investigation	1998-1999
Vice President, American Society for Clinical Investigation	2001-2002
President-Elect, American Society for Clinical Investigation	2002-2003
President, American Society for Clinical Investigation	2003-2004
Chair, Special Emphasis Panel, NIH	March 2004
Chair, Special Emphasis Panel, NIH	June 2004
Chair, Special Emphasis Panel, NIH	March 2005
Awards Committee, American Society of Hematology	2003-2006
Councilor, Western Association of Physicians	2004-2007
Vice President, American Society of Hematology	2005-2006
President-Elect, American Society of Hematology	2006-2007
President, American Society of Hematology	2007-2008
Review Board, Howard Hughes Medical Institute	2006-
Regular Member, NIH Hematopoiesis Study Section	2009-2011
NIDDK Council, Permanent Member	2011-2015
Association of American Physicians, Councilor	2011-2015
Secretary, Greater New York Hospital Association	2013-2014
Treasurer, Greater New York Hospital Association	2014-2015
Vice Chair, Board of Directors, Greater New York Hospital Association	2015-
Member, Scientific Advisory Board, New York Genome Center	2013-
Member, NIH Director's Multi-Council Working Group on Big Data	2014-
Chair-elect, Greater New York Hospital Association Board	2016-2017
Chair, Greater New York Hospital Association Board	2017-2018
Member, SUNY Research Council	2017-

Prior University Responsibilities

University of Washington

Institutional Cancer Funding Committee	1994-2002
Fellowship Research Training	1987-2002
Representative to Faculty Senate	1991-1994
Medical Scientist Training Program Advisory Board	1994-1997
Thesis Committee, 6 Graduate Students	1996-2002
Medical Scientist Training Program Executive Council	1997-2002
Dean's Council on Scientific Affairs	1995-1998
Department of Medicine Appointments and Promotions Committee	1998-2000
Department of Medicine Professors Review Committee	2000-2002
School of Medicine Council on Research and Graduate Education	2001-2002

University of California San Diego

Chairman, Department of Medicine	2002-2010
Co-Chair, Transition Committee, Cancer Center	2002
Member, Biomedical Sciences Graduate Program Council	2002-2010
Search Committee, Physician-in-Chief	2002
Chair, Search Committee, Cancer Center Director	2002-2003
Member, Research Council, UCSD School of Medicine	2002-2010

Member, Board of Governors Executive Committee, UCSDMC	2002-2010
Member, Chief, Ambulatory Operations Search Committee	2003
Co-Director, HHMI sponsored Med into Grad program	2005-2010
Member, Moores Cancer Center Cabinet	2005-2010
Chair, Search Committee, Chair of Cellular and Molecular Medicine	2005-2006
Member, Search Committee Vice Chancellor for External Affairs	2005-2006
Chair, Search Committee Dean for Scientific Affairs	2007-2008

Invited Academic Lectures over the past 20 years

Invited Speaker, Keystone Symposium on Megakaryocytes and Platelets, Lake Tahoe, CA, January 10-15, 1998.

Invited Speaker, Vascular Biology Affinity Group, Scripps Research Institute, La Jolla, CA, January 30, 1998.

Invited Speaker, University of Vermont Biochemistry Lecture Series, Burlington, VT, February 13, 1998.

Medical Grand Rounds, University of Alabama at Birmingham, Birmingham, AL; March 5, 1998.

Invited Speaker, 6th International Symposium on Hematopoietic Stem Cell Transplantation, San Diego, CA; April 16-18, 1998.

Plenary Lecture, Annual Meeting of the British Society of Hematology, Glasgow, Scotland; April 27, 1998.

Blood Club of the University of Minnesota, Minneapolis, MN; May 13, 1998.

Hematology-Oncology Grand Rounds, Ohio State University, Columbus, Ohio; May 29, 1998.

Reissmann Lecture, Medical Grand Rounds, Kansas University, Kansas City, KS; June 3, 1998.

Invited Speaker, Gordon Conference on Thrombosis, Plymouth, NH; June 28-July 3, 1998.

Invited Speaker, Hematopoietic Stem Cell Meeting, Meersberg, Germany; July 2-4, 1998.

Plenary Lecture, European Hematology Association Annual Meeting, Amsterdam, The Netherlands; July 4-8, 1998.

Invited Speaker, Australasian Society of Blood Transfusion Annual Meeting, Sydney, Australia; July 15-18, 1998.

Invited Speaker, NHLBI Workshop on Research in Transfusion Medicine. Bethesda, MD. Sept 15-16, 1998.

The Lori Strauss Lecture, Medical Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY. October 9, 1998.

Invited Speaker, 3rd Argentine Congress on Thrombosis and Hemostasis, Buenos Aires, Argentina; November 18-20, 1998.

Meet-The-Expect Speaker, American Society of Hematology Annual Meeting. Miami Beach, FL. December 6, 1998.

Invited Speaker, Clinical Hematology and Oncology: 1999, La Jolla, CA. February 14-17, 1999.

Invited Speaker, Acute Leukemia Forum 1999, San Francisco, CA. April 16, 1999.

Plenary Lecture, ASCI/AAP Annual Meeting, Chicago, IL. April 24-25, 1999.

Invited Speaker, Fifth International Congress on Biological Response Modifiers, Toronto, Canada. April 29-May 1, 1999.

Invited Speaker, Beijing Union Medical Center Hospital, Beijing, China. May 10, 1999.

Invited Speaker, Xijing Hospital, Xi'an, China. May 12-13, 1999.

Invited Speaker, International Society for Experimental Hematology, Monte Carlo. July 10-14, 1999.

Plenary Lecture, International Society of Thrombosis and Hemostasis, Washington DC. August 14-21, 1999.

Invited Speaker, 24th European Symposium on Hormones and Cell Regulation. Strasbourg, France; Sept 24-27, 1999.

Invited Speaker, 9th Congress of the International Society of Hematology, Asian/Pacific Division, Bangkok, Thailand; October 24-28, 1999.

Invited Speaker, Acute Leukemia and Bone Marrow Transplantation 2000, Haifa, Israel; November 16, 1999.

Medical Grand Rounds, University of Washington School of Medicine, Seattle, WA. Feb 14, 2000.

Invited Speaker, Acute Leukemia Forum 2000, San Francisco, CA. March 31, 2000.

Hematology-Oncology Grand Rounds, Mt Sinai School of Medicine, New York, NY. April 20, 2000

Dameshek Visiting Professorship, Tufts University School of Medicine, Boston, MA. May 4-5, 2000.

Invited Speaker, 13th Symposium on the Molecular Biology of Hematopoiesis, New York, NY. July 14-18, 2000.

Invited Speaker, International Conference and Workshop on Hematopoietic Stem Cells, Tubingen, Germany. September 14-16, 2000.

Invited Speaker, Western Australia Institute for Medical Research, Perth, Australia. Oct 20-25, 2000.

Invited Speaker, University of Wisconsin and Blood Center of Southeast Wisconsin. Nov 10, 2000.

Plenary Lecture, Japanese Society of Hematology Annual Meeting, Nagoya, Japan. April 19, 2001.

Invited Speaker, Acute Leukemia Forum 2001, San Francisco, CA. April 20, 2001.

Invited Speaker, European Society of Hematology Annual Meeting, Frankfurt, Germany. June 21-24, 2001.

Invited Speaker, Clinical Aspects of Myeloproliferative Disorders, New York, NY. October 24-27, 2001.

Invited Speaker, Myeloproliferative Disorders, ASH Meeting, December 7, 2001

Invited Speaker, Gordon Conference on Hemostasis, Colby College, July 7-12, 2002

Medical Grand Rounds, UCSD Medical Center, San Diego, CA, August 14, 2002

Invited Speaker, ISH Meeting, Seoul, South Korea. August 24-28, 2002

Invited Speaker, Scientific Subcommittee on Pediatrics, ASH meeting, Dec 2002

Medical Grand Rounds, University of California at Davis, Jan 16, 2003

Invited Speaker, AAAS Seminar on Science in Medicine, Denver CO; Feb 8, 2003

Annual Corky Tanaka Lecturer, Harbor General Hospital, Torrance, CA; Mar 18, 2003

Invited Speaker, Society of Experimental Biology and Medicine Seminar on Physician-Scientists, San Diego, CA; April 14, 2003

26th Annual Weiner lecturer – New York Blood Center, May 12, 2003

Presider, Department of Medicine Research Days, and Medical Grand Rounds, University of Texas San Antonio, May 19-21, 2003

State of the Art Lecture, International Society of Thrombosis and Hemostasis, Birmingham, England. July 12-18, 2003

Invited Speaker, 2nd International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. New York, NY, October 16-18, 2003.

Invited Speaker, Scientific Subcommittee on Laboratory Medicine, ASH Annual Meeting. Dec 6-9, 2003

Invited Speaker, Meet-the-Expert Session, ASH Annual Meeting, Dec 6-9, 2003

Ross Kyger Visiting Professor, University of Pennsylvania School of Medicine, April 5-6, 2004

Invited speaker, American Society of Pediatric Hematology/Oncology annual meeting, April 30-May 2.

Invited Speaker, Gordon Conference on Hemostasis and Thrombosis, Colby, ME, July 11-16, 2004

Invited Speaker, Fifth Biennial International Symposium on Hematopoietic Stem Cells, Tübingen, Germany, September 16 to 18, 2004

Invited Speaker, Lund University, Lund, Sweden, Sept 20-21, 2004

Medical Grand Rounds, University of Michigan School of Medicine, Ann Arbor, MI, October 21, 2004

Tibor Greenwalt Scientific Lecture and Award, American Association of Blood Banks Annual Meeting, Baltimore, MD, October 24, 2004

Louis Wasserman Lecture, Mt Sinai School of Medicine, New York, NY, November 19, 2004

Hettig Lecturer, Baylor University, Houston, TX, January 26-27, 2005

Vice-Chair and Invited Speaker, Gordon Research Conference on Cell Biology of Megakaryocytes and Platelets, Santa Barbara, CA, March 6-11, 2005

Moderator, Acute Leukemia Forum, San Francisco, CA, April 8, 2005

Annual Goldberg Lecturer, UCLA-Cedars-Sinai Medical Center, Los Angeles, CA, November 16-17, 2005

Invited Speaker, Scientific Subcommittee on Hematopoietic Growth Factors, American Society of Hematology Annual Meeting, Atlanta, GA, December 3-6, 2005

Chair and Plenary Session Speaker, American Society of Hematology Annual Meeting, Atlanta, GA, December 3-6, 2005

Plenary Session Speaker, Western Association of Physicians Annual Meeting, Carmel CA, Feb 2, 2006

Moderator, Acute Leukemia Forum, San Francisco, CA March 31, 2006

Invited Speaker, Digestive Diseases Week, Los Angeles, CA, May 23, 2006

Invited Speaker, INSERM U506 Research Meeting, Paris, France, June 12, 2006

Invited Speaker, 9th Symposium on Stem Cell and Hematopoiesis, Tokyo, Japan, November 3, 2006

Invited Speaker, 39th annual meeting of the American Society of Nephrology, San Diego, CA, Nov 14, 2006

Meet the Expert Speaker, American Society of Hematology Annual Meeting, Orlando, FL, December 9, 2006

Chair, Gordon Research Conference on Cell Biology of Megakaryocytes and Platelets, Santa Barbara, CA, March 4-9, 2007

Physician-in-Chief Pro Tempore, Brigham and Women's Hospital and Harvard Medical School, March 20-23, 2007

Invited Speaker, 98th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007

UC San Diego Annual Faculty Research Lecture/Award, San Diego, CA, May 11, 2007

Tyndale Lecture, University of Utah, Salt Lake City, UT, May 31, 2007

Keynote Address, Cytopenias 2007, San Diego, CA, Oct 5, 2007.

Keynote Address, American College of Physicians California Regional Meeting, Indian Wells, CA, Oct. 20, 2007

Invited Speaker, AACR-ASH Workshop on PI3-Kinase, Lansdowne, VA, March 3-5, 2008

Invited Speaker, Korean Society of Hematology, Seoul, Korea, May 29-31, 2008

Invited Speaker, Japanese Society of Hematology annual meeting, Oct 10-12, 2008.

Invited Speaker, University of Miami Medical Grand Rounds, Miami, FL. Feb 11, 2009

Invited Speaker, Ikeda Lecture, Tokyo, Japan, March 30, 2009

Solomon Berson Visiting Professorship, Medical Grand Rounds, Mt. Sinai School of Medicine, New York, NY, April 13, 2009

Invited Speaker, American College of Physicians Annual Meeting, Philadelphia, PA, April 24, 2009

Invited Speaker, 1st Annual Symposium on Translational Medicine, Rome, Italy, May 6-8, 2009

Invited Speaker, International Highlights of ASH, Sao Paulo, Brazil, May 12-16, 2009

Invited Speaker, International Society of Thrombosis and Hemostasis, Boston, MA, July 13-17, 2009

Invited Speaker, American Society of Hematology Clinical Research Training Institute, San Diego, CA, August 2-7, 2009

Invited Speaker and Session Chair, American Society of Hematology Annual Meeting Education Session on Platelets, Dec 5, 2009

Invited Speaker, Highlights of ASH, Los Angeles, CA, to be held: January 29-30, 2010

Invited Speaker, Highlights of ASH, San Francisco, CA, to be held: Feb 5-6, 2010

Clement Finch Lecturer, University of Washington Medical Grand Rounds, Feb 18-19, 2010

Invited Speaker, Annual Meeting Royal College of Pathology, Australia, Melbourne, Australia, Feb 24-28, 2010

Invited Speaker and Co-Director, ASH/EHA Translational Research Training in Hematology Program, Madeira, Spain, March 21-26, 2010

Invited Speaker, Indiana University, May 5-6, 2010

Invited Speaker, Update in Cancer Medicine and Hematology, Harvard School of Medicine, "Thrombocytopenia", October 2010

Invited Speaker, 60th Anniversary NIDDK Special Seminar, American Society of Hematology Annual Meeting, December 2010

Annual Lacher Lecture, Memorial Sloan-Kettering Cancer Center, New York, NY, May 20, 2011

Invited Speaker, Update in Cancer Medicine and Hematology, Harvard School of Medicine, "Thrombocytopenia", October 2011

Myelofibrosis: An Old Disease with New Developments, Myelofibrosis Satellite Symposium, American Society of Hematology Annual Meeting, San Diego, CA, December 9, 2011

Acute Leukemia Forum, Moderator, San Francisco, CA, April 20, 2012

Plenary Lecture: Thrombopoietin: From Cloning to Clinic, Korean Society of Hematology Annual Meeting, June 1, 2012

Presidential Plenary Talk: From Genes to Therapy, International Society for Thrombosis and Hemostasis Annual Meeting, Liverpool, England, June, 2012

Thrombocytopenia, Harvard Update on Hematology and Oncology, Boston, MA, September 23, 2012

Hematology-Oncology Grand Rounds, Brigham and Women's Hospital, September 25, 2012

Medical Grand Rounds, University of California, San Diego, October 3, 2012

Thrombocytopenia, Beth Israel, New England Deaconess CME Course, Santa Fe, NM October 2012

Landsteiner Memorial Lecturer, American Association of Blood Banks Annual Meeting, Boston, MA October 9, 2012

Medical Grand Rounds, University of Pennsylvania, January 2013, Philadelphia, PA

MSTP Lecture, University of Connecticut, February, 2013, Farmington, CT

Medical Grand Rounds, University of Washington, April 2013, Seattle, WA

Acute Leukemia Forum, Moderator, San Francisco, CA, April 2013

Medical Grand Rounds, Johns Hopkins University, Baltimore, MD, May 2013

Thrombocytopenia, Harvard Update on Hematology and Oncology, Boston, MA, October, 2013

Thrombocytopenia, Beth Israel, New England Deaconess CME Course, Santa Fe, NM October 2013

Beutler Memorial Lecture, American Society of Hematology, New Orleans, LA, December 2013

Invited Lecture, NIDDK Special Symposium on Marrow, Kidney and Liver Fibrosis, January 7, 2014

Thrombocytopenia, Harvard Update on Hematology and Oncology, Boston, MA, October, 2014

Thrombocytopenia, Beth Israel, New England Deaconess CME Course, Santa Fe, NM, October 2014

Invited Lecture, UCLA Jonson Cancer Center, November 13, 2014

Acute Leukemia Forum, Moderator, San Francisco, CA, March 26, 2015

Thrombocytopenia, Harvard Update on Hematology and Oncology, Boston, MA, September 27, 2015

Thrombocytopenia, Beth Israel, New England Deaconess CME Course, Santa Fe, NM, October 21, 2015

Keynote Speaker, Earl Davie Symposium, Vancouver, British Columbia, November 23, 2015

Acute Leukemia Forum, Moderator, Newport Beach, CA, March 18, 2016

Invited Speaker, Geoffrey P. Herzig Memorial Symposium, University of Louisville School of Medicine, April 8-9, 2016

Thrombocytopenia, Harvard Update on Hematology and Oncology, Boston, MA, September 25, 2016

Plenary Speaker, 9th Congress of the Asian-Pacific Society of Thrombosis and Hemostasis, Taipei, Taiwan, October 8, 2016

Thrombocytopenia, Beth Israel, New England Deaconess CME Course, Santa Fe, NM, October 19, 2016

Hematology Oncology Research Seminar speaker, Mt Sinai School of Medicine, New York, NY, Jan 27, 2017

Medical Grand Rounds, University of California, San Diego School of Medicine, San Diego, CA, March 29, 2017

Visiting Fellowship and Lectures, Institute of Advanced Studies, University of Bologna, April 2017

Thrombocytopenia, Harvard Update on Hematology and Oncology, Boston, MA, to be held September 24, 2017

Thrombocytopenia, Beth Israel, New England Deaconess CME Course, Santa Fe, NM, to be held October 25, 2017

Massachusetts General Hospital Cancer Center Grand Rounds, Harvard School of Medicine, Boston, MA, to be held January 25, 2018

Mentored Fellows, Visiting Scientists, Students and Junior Faculty Members

	<u>Dates</u>	<u>Present Position</u>
Chris Brown, M.D.	1987-1991	Professor of Medicine, University of Calgary
Steve Petersdorf, M.D.	1989-1990	Associate Professor, University of Washington - deceased
Robert Hromas, M.D.	1989-1991	Professor and Chair, Department of Medicine, University of Florida
John McCarty, M.D.	1991-1996	Professor, Virginia Commonwealth University, Director of Bone Marrow Transplantation
Jeff Matous, M.D.	1992-1994	Hematology Practice, Denver, Colorado
Jonathan Drachman, M.D.	1993-1998	Executive Vice President for Research and Development, Chief Medical Officer, Seattle Genetics, Bothell, WA
Maria Jorgensen, M.D., Ph.D.	1993-2000	Oncology Practice, Yakima, Washington
Hannah Linden, M.D.	1994-2002	Associate Professor, University of Washington
Cathy Carow, Ph.D.	1995-2001	Private Enterprise
Yoshi Miyakawa, M.D., Ph.D.	1997-2000	Associate Professor, Keio University, Tokyo, Japan
Keiko Hodohara, M.D., Ph.D.	1997-1998	Head, Blood Services, Kyoto University, Kyoto, Japan
Ponlapat Rojnuckarin, M.D., Ph.D.	1997-2001	Professor, Chulalongkorn University, Bangkok, Thailand
Qin Wang, M.D.	1998-1999	Assistant Professor, Beijing People's Hospital, Beijing, China
Amy Geddis, M.D., Ph.D.	1998-2002	Associate Professor, University of California, San Diego
Tania Habib, Ph.D.	1999-2003	Staff Scientist, Benaroya Research Institute, Seattle, WA
Keita Kirito, M.D., Ph.D.	2001-2004	Professor, Yamanashi University, Japan
Bryan McIntosh Ph.D.	2001-2007	Biomedical Sciences, Staff Scientist, Genlantis Inc., San Diego, CA
Takafumi Nakao M.D., Ph.D.	2003-2005	Assistant Professor, Osaka City University Medical School, Japan
Chris DiSimone, M.D., Ph.D.	2003-2005	Private Oncology Practice, Tucson, Arizona
Supantitra Chanprasert, Ph.D.	2003-2004	Scientist, Department of Clinical Microscopy Chulalongkorn University, Bangkok, Thailand
Ian Hitchcock, Ph.D.	2004-2007	Lecturer in Biomedical Sciences, Centre for Immunology and Infection, University of York, United Kingdom
Ima Budihardjo, M.D., Ph.D.	2005-2007	Post-doctoral Fellow, Univ. Calif. San Diego
Mie Soda, M.D., Ph.D.	2005-2007	Post-doctoral Fellow, Univ. Calif. San Diego

Scott Jung, M.D.	2007–2010	Clinical Research Medical Director, Amgen, Inc. Thousand Oaks, CA
Sebastian Saur	2007-2008	M.D./Ph.D. Student, University of Freiburg, Germany
Veena Sangkhee Ph.D.	2010-2013	Post-doctoral Fellow, Department of Medicine, Univ. Calif. Los Angeles
Huichun Zhan M.D.	2014-	Assistant Professor, Department of Medicine, Stony Brook School of Medicine

Thesis Committee Students

University of Washington

Julie Melo
Katherine Jordan
John Kulman
Henrik Andersen

University of San Diego

Bryan McIntosh
Wendy Roeb
Mark Wahrenbrock
Jennifer Stevenson
Muneera Smith
Daniel Goff
Helen Zhu

Minor Thesis Committee Students

Peter Gent – 2002 – Chair
Nancy Hurtado – 2002 – Co-Chair
Heather McMahon – 2003
Minh-ho Do – 2003- Co-Chair
Jason Goode – 2004 – Chair
Ben Sachs – 2004 – Co-Chair
Jennifer Stevenson – 2005 – Co-Chair
Justin Voog – 2005 – Co-Chair
Alex Joyner – 2006 – Co-Chair

Teaching

I have been involved in medical student, resident, clinical fellow, and research fellow training at the University of Washington. I participated in the second year medical school

course on Hematology, acting as a small group leader, for nearly ten years. As an Attending on the General Medicine, Hematology/ Oncology Inpatient and Hematology Consultation Services at University of Washington Hospital and as intake attending at morning report, I taught interns, residents, and clinical fellows clinical medicine. In the laboratory, I have served as primary mentor for 10 research fellows, five visiting scientists' three PhD thesis students, and numerous rotating graduate students. Finally, as an Adjunct Professor in the Department of Biochemistry at UW I taught a mini-course on the Structure and Function of Hematopoietic Growth Factors and one entitled Blood Coagulation. These courses were 10-lecture colloquia given every other Winter Quarter for Biochemistry and other Graduate students.

At the University of California San Diego I taught as part of attending two or more months on the inpatient University Hospital service, MED401 course, to medical students and residents, participate in morning teaching conference three times weekly throughout the year, teaching medical students and residents, and delivering 4 noon conferences annually, medical grand rounds lectures once to twice a year, a lecture on hematopoiesis to the Medical School Pharmacology course and on stem cells to the Biomedical Sciences Graduate core course and to the California Institute for Regenerative Medicine sponsored course on embryonic stem cells. Starting in 2007, I co-organized and lecture in MED 275, a bedside to bench to bedside course for Med into Grad and Medical Students at UCSD.

At Stony Brook University I teach in the first year Pathology course on hematopoiesis and platelet biology, to the Clinical Scholars course on career choices, to the Global Medicine course on developing a global medicine program, and to the Rising Leaders course on mentoring and leadership, and healthcare policy in academic medicine.

Awarded Patents

US Patent #5,546,536: Inventors: **Kaushansky K**, Hagen FS. Colony-stimulating factor derivatives. 1988

US Patent # 5,989,537: Inventors: Holly RD, Lok S, Foster DC, **Kaushansky K**, Kuijper JL, Lofton-Day CE, Oort PJ. Methods for stimulating granulocyte-macrophage lineage using thrombopoietin. 1999

US Patent #6,099,830: Inventors: **Kaushansky K**. Methods for stimulating erythropoiesis using hematopoietic proteins. August 8, 2000

Australian Patent #725159: Inventor: **Kaushansky K**. Methods for stimulating erythropoiesis using thrombopoietin. October 5, 2000

Australian Patent #723793: Inventors: Holly RD, Lok S, Foster DC, Hagen FS, **Kaushansky K**, Kuijper JL, Lofton-Day CE, Oort PJ, Burkhead SK. Hematopoietic protein and materials and methods for making it. December 21, 2000

US Patent #6,316,254: Inventors: Holly RD, Lok S, Foster DC, **Kaushansky K**, Kuijper JL, Lofton-Day CE, Oort PJ. Methods for stimulating erythropoiesis using hematopoietic proteins. November 13, 2001

International Patent # WO 2004/026332A1: **Kaushansky K**, MacDonald B. Methods of increasing platelet and hematopoietic stem cell production. April 1, 2004.

BIBLIOGRAPHY

Kenneth Kaushansky, M.D.

Peer-Reviewed Papers

1. **Kaushansky K**, Finerman GAM, Schwabe AS: Chronic destructive arthritis in Familial Mediterranean Fever. *Clin. Ortho.* 155:156-161, 1981.
2. **Kaushansky K**, O'Hara PJ, Berkner K, Segal GM, Hagen FS, Adamson JW: Genomic cloning, characterization, and multilineage expression of human granulocyte-macrophage colony-stimulating factor. *Proc. Natl. Acad. Sci. USA* 83:3101-3105, 1986.
3. Broudy VC, **Kaushansky K**, Segal GM, Harlan JM, Adamson JW: Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor. *Proc. Natl. Acad. Sci. USA* 83:7467-7471, 1986.
4. **Kaushansky K**, O'Hara PJ, Hart CE, Forstrom JW, Hagen FS: Role of carbohydrate in the function of human granulocyte-macrophage colony-stimulating factor. *Biochem.* 26:4861-4867, 1987.
5. Broudy VC, **Kaushansky K**, Harlan JM, Adamson JW: Interleukin 1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. *J. Immunol* 139:464-468, 1987.
6. **Kaushansky K**, Lin N, Adamson JW: IL-1 stimulates fibroblasts to synthesize granulocyte/macrophage (GM) and granulocyte (G) colony-stimulating factors: A mechanism for the hematopoietic response to inflammation. *J. Clin. Invest.* 81:92-97, 1988.
7. Fibbe WE, Van Damme J, Billiau A, Duikerken N, Lurvink E, Ralph P, Altrock BW, **Kaushansky K**, Willemze R, Falkenburg JHF: Human fibroblasts produce granulocyte-CSF, macrophage-CSF, and granulocyte-macrophage-CSF following stimulation by IL-1 and poly(rl).poly(rC). *Blood* 72:860-866, 1988.
8. **Kaushansky K**, Broudy VC, Harlan JM, Adamson JW: Tumor necrosis factor-alpha and tumor necrosis factor-beta (lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor, and interleukin-1 in vivo. *J. Immunol.* 141:3410-3415, 1988.
9. **Kaushansky K**, Shoemaker, SG, Alfaro S, Brown C: The hematopoietic activity of granulocyte-macrophage colony-stimulating factor is dependent upon two distinct

- regions of the molecule: A functional analysis based upon the activities of hybrid growth factors. *Proc. Natl. Acad. Sci. USA* 86:1213-1217, 1989.
10. **Kaushansky K**, Miller JE, Morris DR, Wilson CB, Hammond WP: The role of lymphocytes and monocytes in hematopoietic growth factor production by peripheral blood mononuclear cells. *Cell. Immunol.* 122:62-70, 1989.
 11. Xu WD, Firestein GS, Taetle R, **Kaushansky K**, Zvaifler NJ: Cytokines in chronic inflammatory arthritis: Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. *J. Clin. Invest.* 83:876-882, 1989.
 12. Migliaccio G, Migliaccio AR, **Kaushansky K**, Adamson JW: Regulation of murine progenitor cells derived from blasts cell colonies under serum-deprived conditions. *Exp. Hematol* 17:110-115, 1989.
 13. Nemunaitis J, Andrews DF, Crittenden C, **Kaushansky K**, Singer JW: Response of simian virus 40 (SV 40)-transformed, cultured human marrow stromal cells to hematopoietic growth factors. *J. Clin. Invest.* 83:593-601, 1989.
 14. Fibbe WE, Daha MR, Duinkerken N, Lurvink E, Ralph P, Altrock BW, **Kaushansky K**, Willemze R, Falkenburg JHF: Interleukin 1 and poly(rl).poly(rC) induce production of granulocyte-CSF, macrophage-CSF, and granulocyte-macrophage CSF by human endothelial cells. *Exp. Hematol.* 17:229-234, 1989.
 15. Lee MY, **Kaushansky K**, Judkins SA, Lottsfeldt JL, Waheed A, Shaddock RK: Mechanisms of tumor-induced neutrophilia: Constitutive production of colony-stimulating factors and their synergistic actions. *Blood* 74:115-122, 1989.
 16. Delwel R, van Buitenen C, Salem M, Bot F, Gillis S, **Kaushansky K**, Altrock B, Lowenberg B: Interleukin 1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor (GM-CSF) release. *Blood* 74:586-593, 1989.
 17. **Kaushansky K**: Control of granulocyte-macrophage colony stimulating factor production in normal endothelial cells by positive and negative elements. *J. Immunol.* 143:2525-2529, 1989.
 18. Schaafsma MR, Fibbe WE, Van Damme J, Duinkerken N, Ralph P, **Kaushansky K**, Altrock BW, Willemze R, Falkenburg JHF.: Interleukin 6 is not involved in the interleukin 1-induced production of colony-stimulating factors by human bone marrow stromal cells and fibroblasts. *Blood* 74:2619-2623, 1989.
 19. Brown CB, Hart CE, Curtis DM, Bailey MC, **Kaushansky K**: Two neutralizing monoclonal antibodies against human granulocyte-macrophage colony-stimulating factor recognize the receptor binding domain of the molecule. *J. Immunol.* 144:2184-2189, 1990.
 20. Simmons PJ, **Kaushansky K**, Torok-Storb B: Mechanisms of cytomegalovirus-mediated myelosuppression: Perturbation of stromal cell function versus direct infection of myeloid cells. *Proc. Natl. Sci. USA* 87:1386-1390, 1990.
 21. Broudy VC, **Kaushansky K**, Shoemaker SG, Aagarwal B, Adamson JW: Muramyl dipeptide and lipopolysaccharide induce production of hematopoietic growth factors in vivo by different mechanisms. *J. Immunol.* 144:3789-3794, 1990.

22. Lee M-T, **Kaushansky K**, Ralph P, Ladner MB: Differential expression of M-CSF, G-CSF, and GM-CSF by human monocytes. *J. Leukocyte Biol.* 47:275-282, 1990.
23. Bot FJ, Schipper P, Broeders L, Delwel R, **Kaushansky K**, Lowenberg B: Interleukin-1 also induces granulocyte-macrophage colony-stimulating factor in immature normal bone marrow cells. *Blood* 76:307-311, 1990.
24. Shoemaker SG, Hromas R, **Kaushansky K**: IL-3 gene expression is dependent upon AP-1 and a novel transcriptional regulator, NF-IL3-A, in human T-lymphocytes. *Proc. Natl. Acad. Sci. USA.* 87:9650-9654, 1990.
25. Kanakura T, Cannistra SA, Brown CB, Makamura M, Seelig GF, Prosser WW, Hakins JC, **Kaushansky K**, Griffen JD: Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. *Blood* 77:1033-1043, 1991.
26. Schaafsma MR, Falkenburg JHF, Landegent JE, Duinkerken N, Osanto S, Ralph P, **Kaushansky K**, Wagemaker G, Van Damme J, Willemze R, Fibbe WE: In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. *Blood* 78(8):1981-1987, 1991.
27. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, **Kaushansky K**, Firestein GS: Cytokines in chronic inflammatory arthritis: VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor- α . *J. Immunol.* 146:3365-3371, 1991.
28. Meropol NJ, Kreider BL, Lee V-Y, **Kaushansky K**, and Prystowski MB: A neutralizing monoclonal antibody binds to an epitope near the amino terminus of murine granulocyte-macrophage colony-stimulating factor. *Hybridoma* 10:433-447, 1991.
29. Hromas R, Collins SJ, Hickstein DD, Raskind W, Deaven LL, O'Hara P, Hagen FS, **Kaushansky K**: A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. *J. Biol. Chem.* 266:14183-14187, 1991.
30. Hromas R, Collins S, Raskind W, Deaven L, **Kaushansky K**: Hem-1, a potential transmembrane protein, with expression restricted to blood cells. *Biochem. Biophys. Acta* 1090:241-244, 1991.
31. Bavisotto L, **Kaushansky K**, Lin N, Hromas R: Antisense oligonucleotides from the stage-specific myeloid zinc finger gene MZF-1 inhibit granulopoiesis *in vitro*. *J. Exp. Med.* 174:1097-1101, 1991.
32. **Kaushansky K**, Lopez JA, Brown CB: Role of carbohydrate modification in the production and secretion of human granulocyte macrophage colony-stimulating factor in genetically engineered and normal mesenchymal cells. *Biochem.* 31:1881-1886, 1992.
33. **Kaushansky K**: Structure-function relationships of the hematopoietic colony-stimulating factors. *Proteins: Structure, Function and Genetics* 12:1-9, 1992.
34. **Kaushansky K**, Shoemaker SG, Broudy VC, Lin NL, Matous JV, Alderman E, Aghajanian JD, Szklut PJ, VanDyke RE, Pearce MK, Abrams JS: The structure-

- function relationship of interleukin-3. An analysis based on the function of a series of interspecies chimera of gibbon and murine IL-3. *J. Clin. Invest.* 90:1879-1888, 1992.
35. Park J-H, **Kaushansky K**, Levitt L: Transcriptional regulation of interleukin 3 (IL3) in primary human T lymphocytes. *J. Biol. Chem.* 268:6299-6308, 1993.
 36. Deisher TA, Haddix TL, Montgomery KF, Pholman TH, **Kaushansky K**, Harlan JM: The role of protein kinase C in the induction of VCAM-1 expression on human umbilical vein endothelial cells. *F.E.B.S.* 331:285-290, 1993.
 37. Deisher TA, **Kaushansky K**, Harlan JM: Inhibitors of topoisomerase II prevent cytokine-induced expression of vascular cell adhesion molecule-1, while augmenting the expression of endothelial leukocyte adhesion molecule-1 on human umbilical vein endothelial cells. *Cell Adhesion Comm* 1:133-142, 1993.
 38. **Kaushansky K**, Karplus A: The hematopoietic growth factors: Understanding functional diversity in structural terms. *Blood* 82:3229-3240, 1993.
 39. **Kaushansky K**, Shoemaker SG, O'Rork CA, McCarty JM: The coordinate regulation of multiple lymphokine genes by Oct-1, and potentially novel 45 and 43 kDa polypeptides. *J. Immunol.* 152:1812-1820, 1994.
 40. **Kaushansky K**, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle M, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou Th, Foster DC: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. *Nature* 369:568-571, 1994.
 41. Lok S, **Kaushansky K**, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mathewes S, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, O'Hara PJ, Hagen FS, Roth GJ., Foster DC: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production *in vivo*. *Nature* 369:565-568, 1994.
 42. Brown CB, Pihl CE, **Kaushansky K**: Mapping of huGM-CSF domains interacting with the huGM-CSFR alpha subunit. *Eur. J. Biochem.* 225:873-880, 1994.
 43. Derigs HG, Reifel-Miller A, **Kaushansky K**, Hromas RA, Boswell HS: GM-CSF expression is regulated at transcriptional and posttranscriptional levels in a murine bone marrow stromal cell line. *Exp. Hematol.* 22:924-932, 1994.
 44. Brown CB, Beaudry P, Dickinson-Laing T, Shoemaker S, **Kaushansky K**: In-vitro characterization of the human recombinant soluble GM-CSF receptor. *Blood* 85:1488-1495, 1995.
 45. Drachman J, Griffin JD, **Kaushansky K**: Stimulation of tyrosine kinase activity by MPL-ligand (thrombopoietin). *J. Biol. Chem.* 270:4979-4982, 1995.
 46. Mire-Sluis AR, Das RG, Thorpe R, and Participants of the Collaborative Study: Immunological Standardization: The international standard for granulocyte colony stimulating factor (G-CSF). *J Immunol Methods* 179:117-126, 1995.
 47. Mire-Sluis AR, Das RG, Thorpe R, and Participants of the Collaborative Study: Immunological Standardization: The international standard for granulocyte-macrophage colony stimulating factor (GM-CSF). *J Immunol Methods* 179:127-135, 1995.

48. Broudy VC, Lin NL, **Kaushansky K**: Thrombopoietin (*c-mpl* ligand) acts synergistically with erythropoietin, stem cell factor, and IL-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy *in vitro*. *Blood* 85:1719-1726, 1995
49. **Kaushansky K**, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C: Thrombopoietin, the Mpl-ligand, is essential for full megakaryocyte development. *Proc. Natl. Acad. Sci. USA* 92:3234-3238, 1995.
50. Monfardini C, Kieber-Emmons T, VonFeldt, JM, O'Malley B, Rosenbaum H, Godillot AP, **Kaushansky K**, Brown CB, Voet D, McCallus DE, Weiner DB, Williams WV: Recombinant antibodies in bioactive peptide design. *J. Biol. Chem.* 270:6628-6638, 1995.
51. Broudy VC, **Kaushansky K**: Thrombopoietin, the *c-mpl* ligand, is a major regulator of platelet production. *J. Leuk. Biol.* 57:719-725, 1995.
52. **Kaushansky K**: Thrombopoietin: The primary regulator of platelet production. *Blood*, 86:419-431, 1995.
53. **Kaushansky K**, Broudy, VC, Grossmann A, Humes J, Lin N, Ren H-P, Bailey MC, Papayannopoulou Th, Forstrom JW, Sprugel KH: Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. *J. Clin. Invest.* 96:1683-1687, 1995.
54. Sattler M, Durstin MA, Frank DA, Okuda K, **Kaushansky K**, Salgia R, Griffin JD: The thrombopoietin receptor c-Mpl activates JAK2 and TYK2 tyrosine kinases. *Exp. Hematol.* 23:1040-1048, 1995.
55. Fibbe WE, Heemskerk DPM, Laterveer L, Pruijt JFM, Foster D, **Kaushansky K**, Willemze R: Accelerated reconstitution of platelets and erythrocytes following syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. *Blood* 86:3308-3313, 1995.
56. McCarty JM, Yee E, Deisher TA, Harlan JM, **Kaushansky K**: Interleukin-4 induces endothelial vascular cell adhesion molecule-1 (VCAM-1) by an NF- κ B independent mechanism. *FEBS Letters*, 372:194-198, 1995.
57. McCarty JM, Sprugel KH, Fox NE, Sabath DE, **Kaushansky K**: Murine thrombopoietin mRNA levels are modulated by platelet count. *Blood*, 86:3668-3675, 1995.
58. **Kaushansky K**, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC: Thrombopoietin expands erythroid, granulocyte-macrophage and megakaryocytic progenitor cells in normal and myelosuppressed mice. *Exp. Hematol.* 23:265-269, 1996
59. Karsan A, Yee E, **Kaushansky K**, Harlan JM: Cloning of a human Bcl-2 homologue: inflammatory cytokines induce human A1 in endothelial cells. *Blood* 87:3089-3096, 1996.
60. Papayannopoulou Th, Brice M, Farrer D, **Kaushansky K**. Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy. *Exp. Hematol.* 24:660-669, 1996.
61. Ku H, Yonemura Y, **Kaushansky K**, Ogawa M.: Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early-acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. *Blood.* 87:4544-4551, 1996.

62. Sitnicka E, Lin N, Priestley GV, Fox N, Broudy VC, Wolf NS, **Kaushansky K**: The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. *Blood*. 87:4998-5005, 1996.
63. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy VC, Perlmutter R, **Kaushansky K**, Roberts JM: A syndrome of gigantism, tumorigenesis and female sterility in p27Kip-1 deficient mice. *Cell*. 85:733-744, 1996.
64. Matous JV, Langley K, and **Kaushansky K**: Receptor binding of c-kit ligand requires at least two non-contiguous regions of the polypeptide. *Blood*, 88:437-444, 1996
65. **Kaushansky K**, Shoemaker SG, O'Rork C, McCarty J: The regulation of GM-CSF is dependent on a complex interplay of multiple nuclear regulatory proteins. *Mol. Immunol*. 33: 461-470, 1996.
66. Zucker-Franklin D and **Kaushansky K**: The effect of Thrombopoietin on the development of megakaryocytes and platelets: An ultrastructural analysis. *Blood* 88:1632-1638, 1996.
67. Broudy VC, Lin NL, Fox N, Taga T, **Kaushansky K**: Thrombopoietin stimulates CFU-Meg proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. *Blood*, 88: 2026-2032, 1996.
68. Grossmann A, Lenox J, Ren HP, Humes JM, Forstrom JW, **Kaushansky K**, Sprugel KH: Thrombopoietin accelerates platelet, red blood cell and neutrophil recovery in myelosuppressed mice, *Exp. Heme* 24: 1238-1246, 1996.
69. Grossmann A, Lenox J, Deisher T, Ren HP, Humes JM, **Kaushansky K**, Sprugel KH: Synergistic effects of thrombopoietin and G-CSF on neutrophil recovery in myelosuppressed mice. *Blood* 88:3363-3370, 1996.
70. **Kaushansky K**: Megakaryocytes: Their precursors and their progeny. *Trends Cardio Med* 6:261-265, 1996.
71. Drachman JD, Sabath DF, Fox NE, **Kaushansky K**: Thrombopoietin signal transduction in purified murine megakaryocytes. *Blood* 89:483-492, 1997.
72. Wun T, Paglieroni T, Hammond WP, **Kaushansky K**, Foster DC: Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. *Am J Hematol* 54:225-232, 1997.
73. Broudy VC, Lin NL, Sabath DF, Papayannopoulou Th, **Kaushansky K**: Human platelets display high affinity receptors for thrombopoietin. *Blood* 89:1896-1904, 1997.
74. **Kaushansky K**.: Thrombopoietin: The primary regulator of platelet production. *Trends in Endo and Metab* 8:45-50, 1997.
75. Drachman JG, **Kaushansky K**: Dissecting the thrombopoietin receptor: Functional elements of the mpl cytoplasmic domain. *PNAS* 94:2350-2355, 1997.

76. Jin L, Siritanaratkul N, Emery DW, Richard RE, **Kaushansky K**, Papayannopoulou Th, Blau CA: Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci USA. 95:8093-8097, 1998.
77. Li J, Franco RS, Wang Y, Pan HQ, Eaton D, Cheng T, **Kaushansky K**, Dai, W: Megakaryocyte differentiation of HIMeg-1 cells induced by interferon- γ and tumor necrosis factor- α but not by thrombopoietin. Cytokine 10:880-889, 1998
78. **Kaushansky K**: Thrombopoietin. Drug Therapy Series. New Engl J Med. 339:746-754, 1998
79. Camire RM, Pollak ES, **Kaushansky K**, Tracy PB: Secretable human platelet-derived factor V originates from the plasma pool. Blood 92:3035-3041, 1998.
80. **Kaushansky K**: The enigmatic megakaryocyte gradually reveals its secrets. BioEssays. 21: 353-360, 1999
81. Hammond WP, Wun T, Kaplan A, Kaplan S, Paglieroni T, **Kaushansky K**: High concentrations of thrombopoietin activate platelets in vitro. Clin Appl Hemostasis Thrombosis. In press
82. Drachman JG, Millett KM, **Kaushansky K**: Mpl signal transduction requires functional JAK2, not TYK2. J Biol Chem, 274:13480-13484, 1999
83. Sabath DF, **Kaushansky K**, Broudy VC: Deletion of the membrane-distal cytokine receptor homology domain of MPL results in constitutive cell growth and loss of thrombopoietin binding. Blood, 94:365-367, 1999
84. Rojnuckarin P, Drachman JG, **Kaushansky K**: Thrombopoietin-induced activation of the mitogen activated protein kinase pathway in normal megakaryocytes: Role in endomitosis. Blood 94:1273-1282, 1999
85. Sabath DF, Lin N, **Kaushansky K**, Broudy VC: Role of tyrosine 462 of the membrane proximal F'-G' loop of murine mpl in binding of thrombopoietin. Cytokine 12:127-133, 2000
86. Hodohara K, Fujii N, Yamamoto N, **Kaushansky K**: Stromal cell derived factor 1 acts synergistically with thrombopoietin to enhance the development of megakaryocytic progenitor cells. Blood 95:769-775, 2000
87. Linden HM, **Kaushansky K**: The glycan domain of thrombopoietin enhances its secretion. Biochemistry 39: 3044-3051, 2000

88. Martin-Soudant N, Drachman JG, **Kaushansky K**, Nepveu A: CDP/Cut DNA binding activity is down-modulated in granulocytes, macrophages and erythrocytes, but remains elevated in differentiating megakaryocytes. *Leukemia* 14: 863-873, 2000
89. Wang Q, Fox N, **Kaushansky K**: Interferon- α directly represses megakaryopoiesis by inhibiting TPO-induced signaling through induction of SOCS-1. *Blood* 96:2093-2099, 2000
90. Miyakawa Y, Drachman JG, Gallis B, Kaushansky A, **Kaushansky K**: A Structure-function analysis of serine/threonine phosphorylation of the thrombopoietin receptor, c-MPL. *J Biol Chem* 275:32214-32219, 2000
91. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper J, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Raymond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, **Kaushansky K**, Holly R, Foster D. Interleukin 21 and IL21R: A novel cytokine-receptor pair involved in NK cell expansion and lymphocyte function. *Nature* 408: 57-63, 2000
92. Pastore S, Giustizieri ML, Macia F, Giannetti A, **Kaushansky K**, Girolomoni G: Dysregulated activation of activator protein 1 (AP-1) in keratinocytes of atopic dermatitis patients with enhanced expression of granulocyte/macrophage-colony stimulating factor. *J Invest Dermatol* 115:1134-1143, 2000
93. Rojnuckarin P, **Kaushansky K**: Megakaryocyte proplatelet formation is dependent on PKC α . *Blood* 97:154-161, 2001
94. Miyakawa Y, Rojnuckarin P, Habib T, **Kaushansky K**: Thrombopoietin induces PI3K and SHP2 activation through Gab and IRS proteins in BaF3 cells and primary murine megakaryocytes. *J Biol Chem* 276:2494-2502, 2001
95. Carow CE, Fox N, **Kaushansky K**: The Kinetics of Endomitosis in Primary Murine Megakaryocytes. *J Cell Physiol* 188:291-303, 2001
96. Geddis A, Fox N, **Kaushansky K**: Phosphatidylinositol 3-kinase (PI3K) is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors. *J Biol Chem* 276: 34473-34479, 2001
97. Rojnuckarin P, Miyakawa Y, Fox NE, Deou J, Daum G, **Kaushansky K**: The roles of PI3K and PKC ζ for thrombopoietin-induced MAP kinase activation in primary murine megakaryocytes. *J Biol Chem* 276: 41014-41022, 2001

98. Sabath DF, Lofton-Day C, Lin N, Lok S, **Kaushansky K**, Broudy VC: Identification and characterization of an isoform of murine Mpl. *Biochim Biophys Acta* 1574:383-386, 2002.
99. Habib T, Senadheera S, Weinberg K, **Kaushansky K**. The common γ chain (γ C) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. *Biochemistry*, 41:8725-31, 2002
100. **Kaushansky K**, Fox NE, Lin NL, Liles WC: Lineage-specific growth factors can compensate for stem and progenitor cell deficiencies at the post-progenitor cell level: An analysis of doubly TPO- and G-CSF receptor-deficient mice. *Blood* 99: 3573-3578, 2002.
101. Zhao S, Zoller K, Masuko M, Rojnuckarin P, Yang XO, Parganas E, **Kaushansky K**, Ihle JN, Papayannopoulou Th, Willerford D, Clackson T, Blau CA. Cooperativity between JAK2 and a second signal, provided either by c-kit or flt-3, triggers extensive self-renewal in primary multipotential hemopoietic cells. *EMBO J.* 21:2159-2167, 2002
102. Drachman JD, Miyakawa Y, Luthi J, Dahlen DD, Raney A, Geddis AE, **Kaushansky K**: Mpl/JAK chimeric receptors: both Jak2 and the membrane proximal domain of Mpl are required for proliferation. *J Biol Chem* 277: 23544-23553, 2002
103. Fox NE, Priestley GV, Papayannopoulou Th, **Kaushansky K**: Thrombopoietin (TPO) expands hematopoietic stem cells (HSCs) in vivo. *J Clin Invest* 110: 389-394, 2002
104. Linden HM, **Kaushansky K**: The glycan domain of thrombopoietin (TPO) acts in trans to enhance secretion of the hormone and other cytokines. *J Biol Chem* 277:35240-35247, 2002.
105. Kyriakides TR, Rojnuckarin P, Reidy MA, Hankenson KD, Papayannopoulou T, **Kaushansky K**, Bornstein P. Megakaryocytes require thrombospondin 2 for normal platelet formation and function. *Blood* 101: 3915-3923, 2003
106. Kirito K, Fox NE, **Kaushansky K**: Thrombopoietin stimulates expression of HoxB4: An explanation for the favorable effects of TPO on hematopoietic stem cells. *Blood* 102:3172-3178, 2003
107. Habib T, Nelson A, **Kaushansky K**. Interleukin 21 activates JAK1 and JAK3 and induces a distinct profile of STAT phosphorylation. *J Clin Allergy Immunol* 112: 1033-1045, 2003

108. Hankins J, Naidu P, Rieman M, Wang W, **Kaushansky K**, Rodriguez-Galindo C. Thrombocytosis in an infant with high thrombopoietin concentrations. *J Pediatric Hematology-Oncology* 26:142-145, 2004
109. Geddis AE, **Kaushansky K**. Megakaryocytes express functional aurora kinase B in endomitosis. *Blood* 104:1017-1024, 2004
110. Kirito K, Fox NE, **Kaushansky K**. Thrombopoietin (TPO) induces the nuclear translocation of HoxA9 in hematopoietic stem cells (HSC): A potential explanation for the favorable effects of TPO on HSCs. *Mol Cell Bio.* 24:6751-62, 2004.
111. Fox NE, **Kaushansky K**: Engagement of integrin $\alpha 4\beta 1$ enhances thrombopoietin induced megakaryopoiesis. *Exp Hematol*, 33:94-99, 2005
112. Kirito K, Fox NE, **Kaushansky K**: Thrombopoietin enhances expression of vascular endothelial cell growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1 α . *Blood* 105:4258-4263, 2005
113. **Kaushansky K**. The molecular mechanisms that control thrombopoiesis. *J. Clin Invest.* 115:3339-3347, 2005
114. Chanprasert S, Geddis AE, Barroga C, Fox NE, **Kaushansky K**. Thrombopoietin (TPO) induces *c-myc* expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKC ζ or mTOR in TPO-dependent cell lines and primary megakaryocytes. *Cell Signaling*, 2005 18: 1212-1218
115. Geddis AE, Fox NE, **Kaushansky K**: The Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin (TPO) levels. *Exp Hematol.* 34: 82-86, 2006
116. Féral CC, Rose DM, Han J, Fox NE, Silverman GJ, **Kaushansky K**, Ginsberg MH. Blocking the $\alpha 4$ integrin-paxillin interaction selective impairs lymphocyte recruitment to inflammatory sites. *J. Clin. Invest.* 116: 715-723, 2006
117. Geddis AE, **Kaushansky K**. Endomitotic megakaryocytes form a midzone in anaphase but have a deficiency in cleavage furrow formation. *Cell Cycle.* 2006; 5:538-545
118. **Kaushansky K**. Lineage specific hematopoietic growth factors. *New Engl. J Med.* 354:2034-2045, 2006
119. Coleman TR, Westenfelder C, Toegel FE, Yang Y, Hu Z, Swenson L, Leuvenink HGD, Ploeg RJ, d'Uscio LV, Katusic ZS, Ghezzi P, Zanneti A, **Kaushansky K**, Fox NE, Cerami A, Brines M. Cytoprotective doses of erythropoietin (EPO) or

- carbamylated EPO have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA. 103:5965-70, 2006
120. Geddis AE, Fox NE, Tkachenko E, **Kaushansky K**. Low ploidy endomitotic megakaryocytes exhibit cleavage furrow regression following furrow ingression. Cell Cycle 6:455-460, 2007
 121. Hitchcock IS, **Kaushansky K**. Thrombopoietin promotes β 1 integrin-mediated adhesion in hematopoietic cells via the small GTPase Rap1. Exp Hematology, 2007;35:793-801
 122. Kirito K, Sakoe K, Mitumori T, Nagashima T, Kunitama M, Nakajima K, Nosaki Y, Shinoda D, Takiyama Y, **Kaushansky K**, Komatsu N. A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies. Hematologica 2008; 93:155-156.
 123. Hitchcock I, Fox NE, Prevost N, Sear K, **Kaushansky K**. Roles of Focal Adhesion Kinase (FAK) in megakaryopoiesis and platelet function: Studies using a megakaryocyte lineage-specific FAK knockout. Blood 2008; 111:596-604
 124. Nakao T, Geddis AE, Fox NE, **Kaushansky K**. PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27^{Kip1} Cell Cycle, 2008; 7:257-266
 125. Geron I, Abrahamsson A, Kavalerchik E, Barroga C, Gotlib J, Hood J, Soll R, Noronha G, Durocher J, Tefferi A, **Kaushansky K**, Jamieson C. Selective inhibition of JAK2 driven erythroid differentiation potential of polycythemia vera progenitors. Cancer Cell, 2008; 13:321-330
 126. McIntosh B, **Kaushansky K**: Marrow stromal production of thrombopoietin is regulated by transcriptional mechanisms in response to platelet products. Exp. Hematol. 2008, 36:799-806.
 127. Yoshida K, Kirito K, Yongzhen H, Ozawa K, **Kaushansky K**, Komatsu N. Thrombopoietin (TPO) regulates HIF-1 α levels through generation of mitochondrial reactive oxygen species. Int. J. Hematol. 2008 88:43-51
 128. Hitchcock I, Chen M, Fox NE, **Kaushansky K**. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 2008 112:2222-2231
 129. Barroga C, Pham H, **Kaushansky K**. Thrombopoietin regulates c-myc expression by modulating microRNA (miR)150 expression. Exp Hematol. 2008;36:1585-1592
 130. Soda M, Willert K, **Kaushansky K**, Geddis A. Inhibition of GSK-3 α promotes survival and proliferation of megakaryocytic cells through β -catenin-independent signaling. Cell Signal. 2008 20:2317-2323

131. Saur SJ, Sangkhae V Geddis, AE, **Kaushansky K**, Hitchcock IS. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. *Blood*. 2010;115:1254-1263
132. Jung AS, Kaushansky A, Macbeath G, **Kaushansky K**. Tensin 2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling. *Cell Cycle*. 2011; 10:1838-1844.
133. Wang YV, Leblanc M, Fox N, Mao J-H, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, **Kaushansky K**, Wahl GM. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. *Genes and Development*. 2011, 25:1426-1438
134. Etheridge SE, Roh ME, Cosgrove ME, Sangkhae V, Fox NE, Chen J, Lopez JA, **Kaushansky K**, Hitchcock IS. JAK2V₆₁₇F-Positive Endothelial Cells Contribute to Clotting Abnormalities in Myeloproliferative Neoplasms. *Proc Nat Acad Sci USA* 2014; 111:2295-2300
135. Hitchcock IS and **Kaushansky K**. TPO: From beginning to end. *British J. Haematol. Br J Haematol*. 2014; 165:259-268
136. Sangkhae V, Saur SJ, Kaushansky A, **Kaushansky K**, Hitchcock IS. Phosphorylated c-MPL tyrosine 591 regulates thrombopoietin-induced signaling and proliferation. *Exp Hematol*. 2014; 42:477-486
137. Adler BJ, **Kaushansky K**, Rubin CT. Obesity Driven Disruption of Hematopoiesis and the Bone Marrow Niche. *Nat Rev Endo*, 2014; 10, 737–748
138. Sangkhae V, Etheridge SE, **Kaushansky K**, Hitchcock IS. The thrombopoietin receptor, c-MPL, is critical for development of JAK2V617F-positive MPNs. *Blood* 2014; 124: 3956-3963
139. Papayannopoulou T, **Kaushansky K**. Evolving insights into the synergy between erythropoietin and thrombopoietin and the bipotent erythroid/megakaryocytic progenitor cell. *Exp Hematol*. 2016; 44:664-668
140. Zhan H, Ma Y, Lin CH, **Kaushansky K**. JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. *Leukemia*. 2016 30:2332-2341
141. Lin CHS, **Kaushansky K**, Zhan H. JAK2V617F mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms. *Blood Cells, Molecules and Diseases* 2016 62:42-48
142. Zhan H, Lin CHS, Segal Y, and **Kaushansky K**. The JAK2V617F-bearing Vascular Niche Promotes Clonal Expansion in Myeloproliferative Neoplasms. *Leukemia* 2017 *In Press*

Invited Papers, Editorials and Textbook Chapters

1. **Kaushansky K:** The molecular biology of the colony-stimulating factors. *Blood Cells* 13:3-13, 1987.
2. Adamson JW, **Kaushansky K**, Powell JS, and Segal GM: Hormones and blood production. In: *Endocrinology*, L.J. DeGroot (ed.), Orlando, Florida, W.B. Saunders, 2612-2631, 1989.
3. Lee M-T, **Kaushansky K**, and Ladner MB: Regulation of M-CSF, G-CSF, and GM-CSF mRNA and protein secretion in human monocytes. In: *Mechanisms of Action and Therapeutic Applications of Biologicals in Cancer and Immune Deficiency Disorders*. Alan R. Liss, Inc., New York 1989, UCLA Symposium on Molecular and Cellular Biology 100:29-37, 1989.
4. **Kaushansky K:** Structure-function relationship of granulocyte-macrophage colony-stimulating factor. UCLA Symposium on Molecular and Cellular Biology 120:1-10, 1989.
5. **Kaushansky K:** Structure-function relationships of the hematopoietic colony-stimulating factors. In: *Molecular Biology of Haematopoiesis*, L. Sachs, N.G. Abraham, C.J. Wiedermann, A.S. Levine & G. Konwalinka (eds.), Intercept, Ltd., Hampshire, pp. 343-358, 1990, Proc. of the First International Symposium on the Molecular Basis of Hematopoiesis, 1989.
6. Torok-Storb B, Simmons P, Barge A, **Kaushansky K**, Migliaccio AR, and Johnson G: Mechanisms of marrow graft failure. In: *Molecular Biology of Haematopoiesis*, L. Sachs, N.G. Abraham, C.J. Wiedermann, A.S. Levine & G. Konwalinka (eds.), Intercept, Ltd., Hampshire, pp. 589-596, 1990, Proc. of the First International Symposium on the Molecular Basis of Hematopoiesis, 1989.
7. **Kaushansky K**, Brown CB, O'Hara PJ: Molecular modeling of human granulocyte-macrophage colony-stimulating factor. *Intl. J. Cell Cloning* 8 (Suppl. 1):26-34, 1990.
8. **Kaushansky K**, Brown CB, Petersdorf S: Hematopoietic colony-stimulating factors. In: *Biotechnology of Blood*, Jack Goldstein, (ed.), Butterworth Heinemann, Stoneham, MA, 365-395, 1991.
9. Upshall A, Kumar AA, **Kaushansky K**, McKnight GL: Molecular manipulation of and heterologous protein secretion from filamentous fungi. In: *Molecular Industrial Mycology*. S. A. Leong, R. M. Berka (eds.), Marcel Dekker, Inc., N.Y., 31-44, 1991.
10. **Kaushansky K:** The regulation of colony stimulating factor gene expression. In: *Myelodysplastic Syndrome and Cytokines*. T. Miyazaki, F. Takaku, H. Uchino (eds.), Excerpta Medica. International Congress Series 956:21-27, 1991.
11. **Kaushansky K:** Hematopoietic growth factors: The structural basis of functional diversity. In: *Molecular Biology of Haematopoiesis*, N.G. Abraham, R.K. Shadduck, A.S. Levine & F. Takaku (eds.), Intercept, Ltd., Hampshire, Vol. 3 pp. 727-733, 1994. 8th Symposium on Molecular Biology of Haematopoiesis, Basel, July 1993.

12. **Kaushansky K:** The hematopoietic colony-stimulating factors. In: *Biological Approach to Rational Drug Design*, D.B. Weiner, W.V. Williams (eds.), CRC Press, Boca Raton, Florida, Chapter 3, pp. 51-71, 1994.
13. **Kaushansky K:** The molecular and cellular biology of thrombopoietin. *Hematopoietic Therapy: Index and Reviews* 3:1994.
14. **Kaushansky K:** The mpl ligand: Molecular and cellular biology of the critical regulator of megakaryocyte development. *Stem Cells* 12 (Suppl 1), 91-97, 1994.
15. **Kaushansky K, Lok S:** The molecular and cellular biology of thrombopoietin, the MPL ligand. In: *Molecular Basis of Thrombosis and Hemostasis*. KA High, HR Roberts (Eds.), Marcel Dekker, Inc., New York, NY pp. 651-662, 1995.
16. Drachman JG, **Kaushansky K:** Structure and function of the cytokine receptor superfamily. *Current Opinion in Hematology*, 2:22-28, 1995.
17. McDonald TP, Wendling F, Vainchenker W, McCarty JM, Jorgensen MJ, **Kaushansky K:** Thrombopoietin from human embryonic kidney cells is the same factor as c-mpl-ligand. *Blood* 85:292-294, 1995.
18. **Kaushansky K:** Thrombopoietin: the primary regulator of megakaryocyte and platelet production. *Thrombosis and Haemostasis* 74:521-525, 1995.
19. **Kaushansky K:** Physiology and preclinical studies of thrombopoietin: *Current Opinion in Hematology* 2:172-176, 1995.
20. McDonald TP, Sullivan PS, **Kaushansky K:** Defining units for thrombopoietin. *Blood* 85:1975, 1995.
21. **Kaushansky K:** Thrombopoietin: basic biology, clinical promise. *Intl. J. Hematol.*: 62:7-15, 1995
22. **Kaushansky K:** Hematopoietic Growth Factors: The Structural Basis of Functional Diversity. *Stem Cells* 13:89-90, 1995.
23. **Kaushansky K, Lin N, Grossmann A, Sprugel K, Sitnicka E, Broudy V:** Thrombopoietin: biologic expectations, physiologic surprises and clinical promise. *Molecular Biology of Hematopoiesis*, 4: 1995.
24. Grossmann A, Lenox JS, Humes JM, Ren HP, **Kaushansky K.**, Nash RA, Sprugel KH: Biologic effects of thrombopoietin (TPO). *Molecular Biology of Hematopoiesis*, 4, 1995.
25. **Kaushansky K:** Thrombopoietin and platelet development. *Western J Med.*, 164:209-211, 1996
26. **Kaushansky K:** Thrombopoietin: Does the in vitro biology correlate with its in vivo properties? *Vox Sang* 70, Suppl. 3, 41-43, 1996.
27. **Kaushansky K:** The thrombocytopenia of cancer: Prospects for effective cytokine therapy. *Hematology/Oncology Clinics of North America* 10: 431-455, 1996
28. **Kaushansky K., Broudy VC, Sitnicka E, Lofton-Day C, Grossmann A, Sprugel K:** Do the preclinical effects of thrombopoietin correlate with its in vitro properties? *Stem Cells* 14 (Suppl. 1): 108-111, 1996.

29. **Kaushansky K:** Thrombopoietin and the physiology of platelet production. *Leukemia Research*, 20: 705-707, 1996.
30. **Kaushansky K, Broudy VC, Drachman JG:** The TPO Receptor and Signal Transduction. *Thrombopoiesis and the Mpl Ligand: Molecular, Cellular, Preclinical and Clinical Biology*. D Kuter, P Hunt, WP Sheridan and D. Zucker-Franklin, Editors. Humana Press. 1996
31. **Kaushansky K:** Thrombopoietin: Biological and preclinical properties. *Leukemia* 10:Suppl. S46-48, 1996
32. **Kaushansky K:** Thrombopoietin: In vitro predictions, in vivo realities. *A J Hematol* 53:188-191, 1996.
33. **Kaushansky K:** Thrombopoietin: Understanding and manipulating platelet production. *Ann Rev Med* 48:1-11, 1997.
34. **Kaushansky K:** Thrombopoietin: Platelets on Demand? *Ann Int Med* 126:731-733, 1997.
35. **Kaushansky K:** In vitro predictions, in vivo realities. *Platelets* 8: 444-445, 1997.
36. **Kaushansky K:** Regulation of Megakaryopoiesis. In: *Thrombosis and Hemorrhage*, eds: J Loscalzo, AI Schafer. Williams and Wilkins Press, 1997.
37. **Kaushansky K:** Thrombopoietin: More than a lineage-specific megakaryocyte growth factor. *Stem Cells* 15 (Suppl. 1): 97-103, 1997.
38. **Kaushansky K:** Thrombopoietin: the primary regulator of megakaryocyte and platelet production. *Thromb. Hemost.* 74:521-525, 1997
39. **Kaushansky K:** Thrombopoietin: Basic biology and clinical promise. *Leukemia* 11 (Suppl.3): 426-427, 1997.
40. **Kaushansky K:** New Year's greetings from a new Editor. *Blood* 91:1-3, 1998
41. Broudy VC, **Kaushansky K:** Biology of thrombopoietin. *Curr Op Peds*, 10:60-64, 1998.
42. **Kaushansky K:** Thrombopoietin and the hematopoietic stem cell. *Blood* 92:1-3, 1998.
43. **Kaushansky K:** The role of the MPL receptor in myeloproliferative disorders. *Leukemia* 12 (Suppl. 1): S47-S50, 1998.
44. Drachman JG, Rojnuckarin P, **Kaushansky K:** Thrombopoietin signal transduction: Studies from cell lines to primary cells. *Methods*, 17:238-249, 1999.
45. **Kaushansky K:** Evolution in Blood. *Blood* 93:1441-1442, 1999.

46. **Kaushansky K:** Thrombopoietin and hematopoietic stem cell development. *Ann New York Acad Sci* 872:314-319, 1999.
47. **Kaushansky K:** Thrombopoietin: From theory to reality. *Thrombosis and Hemostasis* 82:312-317, 1999
48. **Kaushansky K:** Biochemical and physiological properties of the hematopoietic growth factors and receptors, and their role in hematologic disorders. In: *Molecular Basis of Blood Diseases, 3rd Edition*. Eds.: G. Stamatoyannopoulos, A. Neinhuis, P Majerus, H Varmus. WB Saunders Publisher, 2000.
49. **Kaushansky K:** Platelet Stimulating Agents. In: *Cancer: Principles and Practice of the Biological Therapy of Cancer, 3rd Edition*. Ed: S Rosenberg. Lippincott, Williams and Wilkins, Publisher. 2000
50. **Kaushansky K:** Use of thrombopoietic growth factors in acute leukemia. *Leukemia*. 14: 505-508, 2000
51. **Kaushansky K:** Blood: New Designs for a New Millennium. *Blood* 95:1-6, 2000
52. **Kaushansky K, Begley CG:** Thrombopoietin: Basic Biology, Clinical Effects. Hematopoietic stem cell transplantation 2000: 1-21.
53. **Kaushansky K:** Glossary of Molecular Biology Terminology. *Hematology (Am Soc Hematol Educ Program)* 438-456, 2000
54. **Kaushansky K:** CAMT: New findings, new questions. *Blood* 97:1-2, 2001
55. **Kaushansky K:** Inside Blood: a roadmap to the best and brightest. *Blood* 97:3, 2001
56. Drachman JG, **Kaushansky K:** The role of Mpl in megakaryopoiesis. In: *Hematopoiesis: A Developmental Approach*. Ed: L Zon. Oxford University Press, Publisher. 2001
57. **Kaushansky K:** Multiple myeloma: multiple ways to defeat erythropoiesis. *Blood* 97:1153, 2001
58. **Kaushansky K:** Access to the biomedical literature: a stand against coercion. *Blood* 97:2195-2196, 2001
59. **Kaushansky K:** Small molecule mimics of hematopoietic growth factors: improving on Mother Nature? *Leukemia* 15:673-674, 2001
60. **Kaushansky K, Roth G:** Megakaryocyte Development and Platelet Function. In: *Wintrobe's Clinical Hematology*. Ed: Lee, Foerster, Lukens, Greer, Rodgers, Lippincott, Williams and Wilkens, Publisher. *In Press*
61. **Kaushansky K:** Hematopoietic growth factor mimetics. *NY Acad Sci* 938:131-138, 2001

62. **Kaushansky K:** The vWF-cleaving protease: new opportunities in TTP. *Blood* 98: 1643-1644, 2001
63. **Kaushansky K:** Removing the cloud from industry-sponsored, multicentered clinical trials. *Blood*: 98:2001-2, 2001.
64. Geddis AE, Linden HM, **Kaushansky K:** Thrombopoietin: A pan-hematopoietic cytokine. *Cytokine and Growth Factor Reviews* 13:61-73, 2002
65. **Kaushansky K,** Drachman JG: The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. *Oncogene* 21: 3359-3367, 2002
66. **Kaushansky K:** Mpl and the hematopoietic stem cell. *Leukemia* 16:738-739, 2002
67. **Kaushansky K:** Etiology of the Myeloproliferative Disorders: The role of thrombopoietin. *Semin Hematol* 40: 6-9, 2003
68. **Kaushansky K:** Celebrate hematology. *Blood* 100:4257-4258, 2002
69. **Kaushansky K:** Glossary of molecular biology terminology. *Hematology (Am Soc Hematol Educ Program)* 490-509, 2002
70. **Kaushansky K:** Thrombopoietin: from theory to reality. *Int J Hematol.* Aug;76 Suppl 1:343-345. 2002
71. **Kaushansky K:** Thrombopoietin: a tool for understanding thrombopoiesis. *J Thrombosis Haemostasis.* 1:1587-1592, 2003
72. **Kaushansky K.** Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell. *Ann N Y Acad Sci;* 996:39-43, 2003
73. **Kaushansky K.** Etiology of the myeloproliferative disorders: The role of thrombopoietin. *Semin Hematol;* 40(Suppl 2):6-9. 2003
74. **Kaushansky K:** Physician-Scientists: Preparations, Opportunities and National Need. *J. Soc Exp Biol Med;* 228:1258-1260, 2003
75. Geddis AE, **Kaushansky K:** Cross Reactivity Between Erythropoietin and Thrombopoietin at the Level of Mpl Does Not Account for the Thrombocytosis Seen in Iron Deficiency. *J Ped Hematol Oncol* 25:919-20, 2003
76. **Kaushansky K.** Mentoring and teaching clinical investigation: In search of Carl Sagans. *J. Clin. Invest.* 114:1165-1168, 2004
77. Geddis AE, **Kaushansky K.** Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. *Curr Opin Pediatr* 16:15-22, 2004
78. **Kaushansky K:** Principles of Signal Transduction, chapter 13 in Williams *Hematology*, 7th ed. 2005

79. **Kaushansky K:** Hematopoietic stem cells, progenitor cells, and cytokines, chapter 15 in *Williams Hematology*, 7th ed. 2005
80. Seligsohn U, **Kaushansky K:** Classification, clinical manifestations and evaluation of disorders of hemostasis, chapter 109 in *Williams Hematology*, 7th ed. 2005
81. **Kaushansky K:** Megakaryopoiesis and Thrombopoiesis, chapter 104 in *Williams Hematology*, 7th ed. 2005
82. **Kaushansky K, Kipps T:** Hematopoietic Agents, Growth Factors, Minerals, and Vitamins, chapter 54 in Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 11th ed. 2005
83. **Kaushansky, K.** On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense. *Blood* 105:4187-4190, 2005
84. **Kaushansky K.** Thrombopoietin and the hematopoietic stem cell. *Ann N Y Acad Sci* 1044:139-141, 2005
85. **Kaushansky K.** Thrombopoietin. Chapter 27, Hemostasis and Thrombosis, ed: Coleman.
86. **Kaushansky K.** On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. *Hematology (Am Soc Hematol Educ Program):* 533-537. 2005
87. Kirito K, **Kaushansky K.** Thrombopoietin stimulates VEGF production in hematopoietic stem cells. *Cell Cycle* 4:1729-1731, 2005
88. Kirito K, **Kaushansky K.** Transcriptional regulation of megakaryopoiesis: TPO signaling and nuclear factors. *Current Opinion in Hematology*, 13: 151-156, 2006.
89. **Kaushansky K.** Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders. *Cytokine Growth Factor Rev.* 17; 423-430, 2006
90. **Kaushansky K, Shattil SJ.** Bloodlines - the importance of mentoring for the future of hematology. *Blood* 109:1353-1354. 2007
91. **Kaushansky K.** The chronic myeloproliferative disorders and JAK2: Dameshek's 54 year old speculation comes of age. *Best Practice & Research Clinical Haematology;* 2007;20:5-12
92. Geddis AE, **Kaushansky K.** Getting to the root of platelet production. *Science*, 2007; 317:1689-1691.
93. Jaffe E, **Kaushansky K.** The American Society of Hematology: A success at age 50. *Blood*, 2008; 111:11-15

94. **Kaushansky K.** Historical review: megakaryopoiesis and thrombopoiesis. *Blood*. 2008; 111:981-986.
95. **Kaushansky K.** Cell expansion and maintenance of stemness. *Blood*. 2008; 111:3920.
96. **Kaushansky K.** Mentoring Physician-Scientists: Repairing the Leaky Pipeline. In *The Vanishing Physician-Scientist*. Ed. Shafer ILR Press, 2009.
97. **Kaushansky K.** Molecular mechanisms of thrombopoietin signaling. *J Thromb Haemost*. 2009; 7 Suppl 1:235-238
98. **Kaushansky K.** Thrombopoietin in normal and neoplastic stem cell development. *Best Pract Res Clin Haematol*. 2009 22:495-499
99. **Kaushansky K.** Determinants of platelet number and regulation of thrombopoiesis. *Hematology Am Soc Hematol Educ Program*. 2009; 147-52
100. **Kaushansky K.** Signal transduction pathways. Chapter 14 in: *Williams Hematology*, 8th ed. 2010. Ed.: Kaushansky
101. **Kaushansky K.** Hematopoietic stem cells, progenitors and cytokines. Chapter 16 in: *Williams Hematology*, 8th ed. 2010. Ed.: Kaushansky
102. **Kaushansky K.** Megakaryopoiesis and thrombopoiesis. Chapter 113 in: *Williams Hematology*, 8th ed. 2010. Ed.: Kaushansky
103. Seligsohn U, and **Kaushansky K.** Classification, clinical manifestations and evaluation of disorders of hemostasis. Chapter 118 in: *Williams Hematology*, 8th ed. 2010. Ed.: Kaushansky
104. **Kaushansky K.** Hematopoiesis and hematopoietic growth factors. Chapter 159, *Cecil Textbook of Medicine*. 2013
105. Carethers J, Coughlin S, Diamond B, Erzurum S, Fried LP, Jameson LJ, **Kaushansky K**, Klotman ME, Lemon S, Mitchell B, Rothman P, Sawyers C, Seidman C and Somlo S. The imperative to invest in science has never been greater. *J Clin Invest*. 2014; 124:3680–3681.
106. Kaushansky A, **Kaushansky K.** Systems biology of megakaryocytes. *Adv Exp Med Biol*. 2014; 844: 59-84.
107. **Kaushansky K.** Thombopoiesis. *Semin Hematol*. 2015; 52: 4-11.
108. Murphy A, Murphy MJ, Begley CG, Stanley ER, Migliaccio AR, **Kaushansky K**, Ng AP, Alexander WS, Hilton DJ, Nicola NA. Tribute to Donald Metcalf. *Stem Cells*. 2015;33:3397-3421

109. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giral S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, **Kaushansky K**, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. *Mayo Clin Proc.* 2015; 90:996-1000
110. **Kaushansky K**. Signal transduction pathways. Chapter 17 in: *Williams Hematology*, 9th ed. 2016. Ed.: K. Kaushansky.
111. **Kaushansky K**. Hematopoietic stem cells, progenitors, and cytokines. Chapter 18 in: *Williams Hematology*, 9th ed. 2016. Ed.: K. Kaushansky.
112. **Kaushansky K**. Megakaryopoiesis and thrombopoiesis. Chapter 111 in: *Williams Hematology*, 9th ed. 2016. Ed.: K. Kaushansky. *In press*
113. Levi M, Seligsohn U, **Kaushansky K**. Classification, clinical manifestations, and evaluation of disorders of hemostasis. Chapter 116 In: *Williams Hematology*, 9th Ed. 2016 Ed.: K. Kaushansky.
114. **Kaushansky K**. Reactive thrombocytosis. Chapter 119 in: *Williams Hematology*, 9th ed. 2016. Ed.: K. Kaushansky.
115. **Kaushansky K**. The Elusive Von Willibrand Factor-Cleaving Protease. *Blood* 2016; 127:2163-2164.
116. **Kaushansky K**. Thrombopoietin and its receptor in normal and neoplastic hematopoiesis. *Thromb J.* 2016;14(Suppl 1):40-43

Abstracts

1. **Kaushansky K**, O'Hara PJ, Berkner K, Segal GM, Broudy VC, Hagen FS, Adamson JW: Genomic cloning and expression of human granulocyte-macrophage colony-stimulating factor: Evidence for multilineage effect of the CSF. *Blood* 66 (Suppl. 1):168a, 1985.
2. **Kaushansky K**, Miller JE, Morris DR, Hammond WP: Hematopoietic growth factors derived from peripheral blood mononuclear cells: Evidence for independent production by purified lymphocytes and monocytes. *Blood* 68 (Suppl. 1):168a, 1986.
3. **Kaushansky K**, Hagen FS, Broudy VC, Adamson JW: Structure-function studies of human granulocyte-macrophage colony stimulating factor: The role of carbohydrate modification. *Blood* 68 (Suppl. 1):167a, 1986.
4. **Kaushansky K**, Broudy VC, Lin N, Adamson JW: Granulocyte-macrophage and granulocyte-colony-stimulating factor are synthesized by candidate cells of the marrow microenvironment in response to IL-1. *Blood* 68 (Suppl. 1):167a, 1986.
5. Broudy VC, Segal GM, **Kaushansky K**, Harlan JM, Adamson JW: Tumor necrosis factor alpha stimulates endothelial cells to produce multilineage hematopoietic growth factors. American Federation for Clinical Research, 1986.
6. **Kaushansky K**, Harlan JM: Genomic sequences involved in the regulation of GM-CSF production in human umbilical vein endothelial cells (HUVES). *Blood* 70 (Suppl. 1):174a, 1987.
7. **Kaushansky K**, Broudy VC, Harlan JM, Adamson JW: Tumor necrosis factor and lymphotoxin stimulate the production of GM-CSF, M-CSF, and IL-1 in vivo. *Blood* 70 (Suppl.1):174a, 1987.
8. Nemunaitis JJ, Andrews DF, **Kaushansky K**, Singer J: SV-40 transformed human stromal cells: Production and response to hematopoietic growth factors. *Blood* 70 (Suppl. 1):181a, 1987.
9. Lee MY, **Kaushansky K**, Judkins SA: Constitutive G-CSF production as a mechanism of tumor-induced granulocytosis. *Blood* 70 (Suppl. 1):262a, 1987.
10. **Kaushansky K**, Shoemaker SG, Alfaro S, Brown C: The hematopoietic activity of granulocyte-macrophage colony-stimulating factor (GM-CSF) is dependent on two distinct domains. *Blood* 72 (Suppl. 1):123a, 1988.
11. Broudy VC, **Kaushansky K**, Adamson JW: Muramyl dipeptide (MDP) induces hematopoietic growth factor production in vivo by a mechanism independent of tumor necrosis factor. American Federation for Clinical Research, 1988.
12. Simmons PJ, **Kaushansky K**, Bowden R, Torok-Storb B: Cytomegalovirus mediated myelosuppression. International Society of Experimental Hematology, 1988.
13. Peterson V, Ralph P, **Kaushansky K**, Sampson-Johannes A, Rundus C: Impact of sepsis on the macrophage-colony-stimulating factor (M-CSF) response to inflammation following thermal injury. *Blood* 72 (Suppl. 1), 1988.

14. **Kaushansky K:** The hematopoietic activity of GM-CSF is dependent on two distinct regions: A functional analysis based on the activities of a series of human-mouse hybrid growth factors and neutralizing monoclonal antibodies. *J Cell Biochem. Suppl.* 13C, 2, 1989.
15. Shoemaker S, **Kaushansky K:** Transcriptional regulation of the human IL-3 gene. *Blood* 74 (Suppl. 1):48a, 1989.
16. Hromas RA, Hickstein D, Aronson E, Collins S, **Kaushansky K:** Human hemopoietic zinc finger genes. *Blood* 74 (Suppl. 1):14a, 1989.
17. Brown C, Hart C, Curtis D, Bailey M, **Kaushansky K:** Two neutralizing antibodies against human (h) GM-CSF recognize the receptor binding domain of the molecule. *Blood* 74 (Suppl. 1):195a, 1989.
18. Schaafsma MR, Falkenberg, JHF, van der Harst D, Duikerken N, Ralph P, **Kaushansky K,** Altrock BW, Brand A, Osanto S, Willemze R, Fibbe WE: Interleukin 2 treatment in cancer patients induces in vivo production of M-CSF and GM-CSF, followed by an increase in the number of circulating hemopoietic progenitor cells. *Blood* 74 (Suppl. 1):46a, 1989.
19. Alvaro-Garcia JM, **Kaushansky K,** Zvaifler NJ, Firestein GS: GM-CSF gene expression and production by rheumatoid (RA) synovial tissue cells. *ASBMB/AAI Meeting*, 1990.
20. Hromas R, Collins S, Bavisotto L, Hickstein D, Raskind W, Deaven L, Hagen FS, **Kaushansky K.:** The myeloid zinc finger gene, MZF-1, is required for granulopoiesis. *Blood* 76 (Suppl. 1): 98a, 1990.
21. Bavisotto L., Hagen FS, Raskind W, Lilly M, Deaven L, **Kaushansky K:** HEM-1, a potential transmembrane protein, is restricted to yet ubiquitous in hematopoietic cells. *Blood* 76 (Suppl. 1): 99a, 1990.
22. Shoemaker SG, **Kaushansky K:** The regulation of IL-3 gene expression: Initial characterization of the positive and negative regulatory proteins and a potential basis of IL-3 tissue specificity. *Blood* 76 (Suppl. 1): 166a, 1990.
23. **Kaushansky K,** Shoemaker SG, Broudy VC, Lin N: Structure-function relationships of IL-3: Mapping of the functional and receptor binding domains. *Blood* 76 (Suppl. 1): 149a, 1990.
24. **Kaushansky K,** Shoemaker S, Lin N, Abrams J, Clark SC: The binding epitopes of a series of IL-3 monoclonal antibodies (mcAb): Definition of four distinct domains and correlation with receptor binding, neutralizing capacity, and the biological activity of IL-3. *Blood* 76 (Suppl. 1): 150a, 1990.
25. **Kaushansky K:** Structure-function relationships of IL-3: Studies based on analysis of interspecies IL-3 chimeric molecules. *J Cell Biochem Suppl.* 15F, 114, 1991
26. Brown CB, Shoemaker SG, **Kaushansky K.:** A soluble form of the huGM-CSF receptor α -subunit binds huGM-CSF. *Blood* 78 (Suppl. 1): 263a, 1991.
27. **Kaushansky K,** McCarty JM: Qualitative and quantitative differences in kB-binding proteins can account for the differential regulation of genes expressed in lymphocytes and endothelial cells. *Blood* 78 (Suppl. 1): 166a 1991.

28. McCarty J, Osborne L, **Kaushansky K**: Gene regulation of vascular cell adhesion molecule-1 (VCAM-1). *Blood* 78 (Suppl. 1), 265a, 1991.
29. Matous JV, Cudkowicz AR, Broudy VC, **Kaushansky K**: Use of interspecies chimeric polypeptides to study the structure-function relationships of stem cell factor (SCF). 1992 Keystone Symposia. *J. Cellular Biochem. Suppl.* 16C:86, 1992.
30. Graves S, Stone D, **Kaushansky K**, Morgan AC: Pertussis toxin B chain in potent biological response modifier. FASEB, 1992.
31. **Kaushansky K**, Shoemaker SG, O'Rork CA, McCarty JM: The coordinate regulation of multiple lymphokine genes is based on the binding of Oct-1 and a potentially novel 50 kDa polypeptide. *Blood* 80 (Suppl. 1):355a, 1992.
32. Park J-H, **Kaushansky K**, Levitt L: Transcriptional regulation of interleukin 3 in primary human T lymphocytes: Role of AP-1 and octamer binding proteins in control of IL3 gene expression. *Blood* 80 (Suppl. 1):348a, 1992.
33. Matous JV, Langley K, **Kaushansky K**: Interspecies chimeric polypeptides help define the structure-function relationships of kit ligand (KL). *Blood* 80 (Suppl. 1):93a, 1992.
34. **Kaushansky K**, Shoemaker S, McCarty JM, O'Rork CA: The transcriptional control of GM-CSF expression. A panoply of positive and negative regulatory elements interact with kB and octamer elements. *Blood* 80 (Suppl. 1):348a, 1992.
35. McCarty JM, Osborn L, **Kaushansky K**: Role of kB binding sites in the inducible and constitutive expression of VCAM-1. *Blood* 80 (Suppl. 1):186a, 1992.
36. Brown CB, Pihl CL, **Kaushansky K**: Mapping of huGM-CSF domains interacting with the huGM-CSFR alpha subunit. TSANZ First International Symposium on "Cytokines in Bone Marrow Transplantation", 6-9 September 1993.
37. Brown CB, Pihl CL, Morcos A, Beaudry P, Shoemaker SG., **Kaushansky K**: Purification and partial characterization of the soluble GM-CSF receptor alpha subunit. *Blood* 82 (Suppl. 1):237a, 1993.
38. Matous JV, Langley K, **Kaushansky K**: *c-kit* ligand (KL) receptor binding involves at least two non-linear regions of KL. *Blood* 82 (Suppl. 1):318a, 1993.
39. **Kaushansky K**, O'Rork C, Shoemaker S: Structure-function relationships of interleukin-3: Lessons learned from other cytokines, model building and mutagenesis. *Blood* 82 (Suppl. 1):319a, 1993.
40. McCarty JM, Yee E, Harlan JM, **Kaushansky K**: IL-4 induces endothelial VCAM-1 by an NF-kB independent mechanism. *Blood* 82 (Suppl. 1):322a, 1993.
41. Williams WV, Kieber-Emmons T, VonFeldt JM, **Kaushansky K**, Brown CB, Voet D, McCallus DE, Weiner DB: Recombinant antibodies in drug design. American Federation for Clinical Research Meeting, Baltimore, MD, April 1994.
42. **Kaushansky K**, McCarty J: The silencing of inflammatory response genes: Lessons learned from GM-CSF and VCAM-1. Annual Inflammation Symposium, Sydney, Australia, May 7-8, 1994.

43. Holly R, Lofton-Day C, Forstrom J, Lok S, Foster D, Broudy VC, **Kaushansky K**: Thrombopoietin: Expression-cloning and biological activity. Presented at European Hematology Association, Brussels, Belgium, June 1994.
44. **Kaushansky K**, Broudy VC, Drachman J, McCarty JM, Jorgensen M, Lok S, Holly RD, Lofton-Day C, Foster DC: The molecular and cellular biology of the MPL-ligand; properties consistent with its identity as Thrombopoietin. Workshop on Megakaryopoiesis, Bethesda, MD, August 18-19, 1994.
45. **Kaushansky K**, Broudy VC, Drachman J, Sprugel K, Foster D: Thrombopoietin: The critical regulator of megakaryocyte development. NIH Conference on Stem Cells, Reno, NV, November 15-17, 1994.
46. **Kaushansky K**, Lin N, Zucker-Franklin D, Broudy VC: Thrombopoietin (Tpo), the Mpl ligand, is the primary regulator of megakaryocyte (Mk) development and maturation. *Blood* 84 (Suppl. 1), 241a, 1994.
47. Sprugel KH, Humes JM, Grossmann A, Ren HP, **Kaushansky K**: Recombinant thrombopoietin stimulates rapid platelet recovery in thrombocytopenic mice. *Blood* 84 (Suppl. 1): 242a, 1994.
48. Papayannopoulou Th, Brice M, **Kaushansky K**: The influence of Mpl-ligand on the development of megakaryocytes from CD34+ cells isolated from bone marrow, peripheral blood and cord blood. *Blood* 84 (Suppl. 1): 324a, 1994.
49. Broudy VC, Lin N, **Kaushansky K**: Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin and stem cell factor to enhance murine megakaryocyte colony growth and increases megakaryocyte polyploidy *in vitro*. *Blood* 84 (Suppl. 1): 330a, 1994.
50. Hammond WP, Kaplan A, Kaplan S, **Kaushansky K**: Thrombopoietin (Tpo) activates platelets *in vitro*. *Blood* 84 (Suppl. 1): 534a, 1994.
51. Drachman JG, Griffin JD, **Kaushansky K**: c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation. *Blood* 84 (Suppl. 1): 390a, 1994.
52. McCarty JM, **Kaushansky K**: Murine thrombopoietin mRNA levels are modulated by platelet count. *Blood* 84 (Suppl. 1): 241a, 1994.
53. Jorgensen MJ, **Kaushansky K**: Thrombopoietin induces megakaryocytic differentiation of embryonic stem cells in culture. *Blood* 84 (Suppl. 1): 329a, 1994.
54. Sabath DF, Drachman JG, **Kaushansky K**, Broudy VC: Development of a cell line dependent on mpl ligand for proliferation. *Blood* 84 (Suppl. 1): 325a, 1994.
55. **Kaushansky K**: Molecular and cellular biology of thrombopoietin, the c-Mpl ligand. The Molecular Biology Society of Japan, Kobe, Japan, December 15-18, 1994.
56. **Kaushansky K**: The Mpl Ligand (ML) is identical to thrombopoietin (Tpo), the critical regulator of megakaryocyte development. ASBMT 1995, Keystone, CO January 26-28, 1995.
57. Fibbe WE, Heemskerk DPM, Laterveer L, Pruijt JFM, Foster D, **Kaushansky K**, Willemze R: Accelerated reconstitution of platelets and erythrocytes following

- syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. *Exp Heme* 23:823, 1995.
58. **Kaushansky K**, Broudy VC, Papayannopoulou Th, Sitnicka E, Grossmann A, Sprugel K: The cellular biology of thrombopoietin: Evidence for both highly specific and wide ranging effects on hematopoiesis. *Exp Heme* 23:840, 1995.
 59. **Kaushansky K**: The cellular biology of thrombopoietin. *Acta Hemat* 93: Preprint 1995, 209, 1995.
 60. **Kaushansky K**: Thrombopoietin: The effects of pleotropic and lineage-specific hematopoietic growth factors. VIIIth Congress, Asian-Pacific Division of International Society of Hematology. Brisbane, Australia. p58, 1995.
 61. **Kaushansky K**: Historical perspectives on thrombopoietin. VIIIth Congress, Asian-Pacific Division of International Society of Hematology. Brisbane, Australia. p132, 1995.
 62. **Kaushansky K**: Thrombopoietin (TPO): A pleotropic hormone? 18th Symposium of the International Association of Comparative Research on Leukemia and Related Diseases. Oct. 29 - Nov. 3, 1995.
 63. Ku H, **Kaushansky K**, Ogawa M.: Thrombopoietin, the ligand for the mpl receptor, synergises with Steel factor and other early-acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. *Blood* 86 (Suppl. 1): 256a, 1995.
 64. Drachman JG, Sabath DF, Frank D, **Kaushansky K**: Thrombopoietin induces tyrosine phosphorylation of JAK and STAT proteins. *Blood* 86 (Suppl. 1): 419a, 1995.
 65. McCarty JM, **Kaushansky K**: Functional characterization of the thrombopoietin promoter. *Blood* 86 (Suppl. 1): 364a, 1995.
 66. Broudy VC, Lin N, Fox N, Atkins H, Iscove N, **Kaushansky K**: Hematopoietic cells display high affinity receptors for thrombopoietin. *Blood* 86 (Suppl. 1): 593a, 1995.
 67. Sitnicka E, Lin N, Fox N, Priestley GV, Broudy V, Wolf NS, **Kaushansky K**: The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. *Blood* 86 (Suppl. 1): 419a, 1995.
 68. Linden H, O'Rork C, Hart CE, Stamm M, Hoffman R, Osborne S, **Kaushansky K**: The structural and functional role of disulfide bonding in thrombopoietin. *Blood* 86 (Suppl. 1): 255a, 1995.
 69. Sabath DF, Drachman JG, **Kaushansky K**, Thorning, D.R., Broudy, V.C.: Tpo induces increased megakaryocytic differentiation in L8057 cells. *Blood* 86 (Suppl. 1): 11a, 1995.
 70. Wun T, Paglieroni T, **Kaushansky K**, Hammond W, Foster D: Thrombopoietin (Tpo) is synergistic with other hematopoietic growth factors (HGF) for platelet activation. *Blood* 86 (Suppl. 1): 912a, 1995.
 71. Grossmann A, Lenox JS, Humes JM, Ren HP, **Kaushansky K**, Sprugel KH: Effects of the combined administration of Tpo and G-CSF on recovery from myelosuppression. *Blood* 86 (Suppl. 1): 371a, 1995.
 72. Broudy VC, Lin N, Fox N, Taga T, **Kaushansky K**: Thrombopoietin stimulates CFU-Meg proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. *Blood* 86 (Suppl. 1): 10a, 1995

73. Papayannopoulou Th, Brice M, Farrer D, **Kaushansky K**: Erythropoietin and thrombopoietin crosstalk in in vitro hemopoiesis. *Blood* 86 (Suppl. 1): 284a, 1995
74. Papayannopoulou Th, Brice M, Farrer D, **Kaushansky, K**. Immunophenotypic features of early and late megakaryocytic progenitors. *Blood* 86 (Suppl. 1): 363a, 1995.
75. **Kaushansky K**: Thrombopoietin: Do its in vitro properties correlate with pre-clinical activities? *Keio Journal of Medicine* 45:277, 1996.
76. Carow CE, Fox NE, **Kaushansky, K**. Purified endomitotic megakaryocytes display a functional cyclin B1-associated mitotic kinase. *Blood* 88 (Suppl. 1):287a, 1996.
77. Drachman JG, **Kaushansky, K**. Dissecting the mpl receptor: Functional subdomains of the cytoplasmic signaling domain. *Blood* 88 (Suppl. 1):447a, 1996.
78. McCarty JM, **Kaushansky K**. Tissue-specific expression of the thrombopoietin (TPO) receptor. *Blood* 88 (Suppl. 1):193a, 1996.
79. Klemsz M, **Kaushansky K**, Cooper R, Cooper S, Broxmeyer H, Hromas R. The thrombopoietin-based truncated mutant fusion cytokines TPOG and TFLOG have multilineage proliferative activity. *Blood* 88 (Suppl. 1):544a, 1996.
80. **Kaushansky K**, Drachman JG, Carow CE. Thrombopoietin: Understanding the mechanisms of megakaryocyte development. Keystone meeting on Hematopoiesis, Tamarron, CO, February 10-16, 1997.
81. **Kaushansky K**, Drachman JG, Carow CE. The molecular basis of megakaryocyte development. 10th Symposium on Molecular Biology of Hematopoiesis. Hamburg, Germany, July 3-6, 1997.
82. **Kaushansky K**. The role of the Mpl receptor and thrombopoietin in acute myelogenous leukemia. 10th Symposium on Molecular Biology of Hematopoiesis. Hamburg, Germany, July 3-6, 1997.
83. Sabath DF, Lin N, **Kaushansky K**, Broudy VC: Tyrosine 462 of murine MPL is important for binding of thrombopoietin. *Blood* 90 (Suppl. 1): 55a, 1997.
84. Linden H, **Kaushansky K**: The glycan domain of thrombopoietin enhances secretion. *Blood* 90 (Suppl. 1): 55a, 1997.
85. Siritanaratkul N, Emery DW, **Kaushansky K**, Blau CA: A cell growth switch using c-mpl and pharmacological inducers of dimerization. *Blood* 90 (Suppl. 1): 553a, 1997.
86. Drachman JG, Millet KM, **Kaushansky K**: Mpl signal transduction requires functional JAK2, not TYK2. *Blood* 90 (Suppl. 1): 598a, 1997.
87. **Kaushansky K**: Molecular mechanisms of megakaryocyte development. Gordon Conference on Hemostasis and Thrombosis, Plymouth, NH, June 28-July 3, 1998.
88. Camire RM, Pollak ES, **Kaushansky K**, Tracy PB: Secretable human platelet derived factor V originates from the plasma pool. Gordon Conference on Hemostasis and Thrombosis, Plymouth, NH, June 28-July 3, 1998.
89. **Kaushansky K**, Rojnuckarin P, Carow CE, Drachman JG: Regulation of megakaryopoiesis. International Society of Hematology/European Hematology Association Annual Meeting. Amsterdam, The Netherlands, July 4-8, 1998.

90. **Kaushansky K:** Thrombopoietin: Implications for the diagnosis and treatment of disorders of platelet production. Australian Society of Hematology Annual Meeting, Sydney, Australia, July 15-18, 1998.
91. **Kaushansky, K:** Towards a greater understanding of megakaryopoiesis. Australian Society of Hematology Annual Meeting, Sydney, Australia, July 15-18, 1998.
92. Jin L, Siritanaratkul N, Emery DW, Richard RE, Priestley GV, Peterson KR, **Kaushansky K**, Papayannopoulou Th, Blau CA: Reversible immortalization of multipotential primary hemopoietic cells. *Exp Heme* 26:800, 1998.
93. **Kaushansky K**, Fox N, Rojnuckarin P, Drachman JG. Stromal cell derived factor (SDF)-1 stimulates megakaryopoiesis through activation of ERK1 and ERK2. *Blood* 92 (Suppl 1): 62a, 1998.
94. Hodohara K, Yamamoto N, **Kaushansky K**. Stromal cell derived factor 1 (SDF-1) acts synergistically with thrombopoietin (TPO) to enhance the development of megakaryocytic progenitor cells (CFU-MK). *Blood* 92 (Suppl 1): 305a, 1998.
95. Sabath DF, **Kaushansky K**, Broudy VC. Deletion of the membrane distal cytokine receptor homology domain of Mpl results in constitutive cell growth. *Blood* 92 (Suppl 1): 674a, 1998.
96. Linden H, **Kaushansky K**. The glycan domain of thrombopoietin (TPO) functions alone in trans to enhance secretion of the receptor binding domain of TPO and other cytokines. *Blood* 92 (Suppl 1): 674a, 1998.
97. Rojnuckarin P, Drachman JG, **Kaushansky K**. Thrombopoietin-induced mitogen-activated protein kinase (MAPK) activation in normal megakaryocytes: Role in endomitosis. *Blood* 92 (Suppl 1): 674a, 1998.
98. Drachman JG, Raney A, Miyakawa Y, **Kaushansky K**. MPL/JAK2 chimeric receptor demonstrates tyrosine kinase activity but is unable to support TPO-induced proliferation. *Blood* 92 (Suppl 1): 63a, 1998.
99. Jorgensen MJ, Raskind WH, Wolff JF, Bachrach HR, **Kaushansky K**. Familial thrombocytosis associated with overproduction of thrombopoietin due to a novel splice donor site mutation. *Blood* 92 (Suppl 1): 205a, 1998.
100. McCarty JM, Melone PD, **Kaushansky K**: Tissue-specific expression of the thrombopoietin (TPO) gene is mediated in part by putative 5' flanking CpG island motifs. *Blood* 92 (Suppl 1): 196a, 1998.
101. Rojnuckarin P, **Kaushansky K**: The mechanisms of proplatelet formation by murine megakaryocytes. International Society of Hematology, Bangkok, Thailand, October 1999
102. Geddis AE, Miyakawa Y, Rojnuckarin P, Fox NE, **Kaushansky K**: Effects of PI3-Kinase inhibition on Mpl signaling in engineered receptor bearing cells and in immature marrow megakaryocytes (MKs). *Blood* 94 (Suppl.1): 654a, 1999
103. Wang Q, Fox NE, **Kaushansky K**: Interferon alpha (IFN-a) inhibits megakaryocyte (MK) development by interfering with thrombopoietin (TPO) induced signaling. *Blood* 94 (Suppl.1): 702a, 1999

104. Miyakawa Y, Drachman JG, Gallis B, Corson M, **Kaushansky K**: The c-Mpl receptor is prominently serine (Ser) phosphorylated in response to thrombopoietin (Tpo) and may contribute to Tpo-induced cell proliferation. *Blood* 94 (Suppl.1): 686a, 1999
105. Rojnuckarin P, **Kaushansky K**: Actin re-organization and proplatelet formation in murine megakaryocytes (MKs): The role of protein kinase C (PKC). *Blood* 94 (Suppl.1): 265a, 1999
106. Miyakawa Y, Himeda C, **Kaushansky K**: Signaling from thrombopoietin receptor, c-Mpl, is not sufficient for terminal monocyte differentiation. *Blood* 94 (Suppl.1): 252a, 1999
107. Carow CE, Fox NE, **Kaushansky K**: The kinetics of endomitosis (EnM) in primary murine megakaryocytes (MKs). *Blood* 94 (Suppl.1): 271a, 1999
108. Drachman JG, Dahlen DD, Miyakawa Y, Luthi J, Mehaffey MG, **Kaushansky K**: The box2 region of c-Mpl is required to support cellular proliferation by enhancing Jak activation and by recruiting a distinct signaling pathway. *Blood* 94 (Suppl.1): 265a, 1999
109. Rojnuckarin P, Miyakawa Y, Habib T, Fox NE, **Kaushansky K**: A multi-protein complex of PI3K, Shp2 and Gab forms in response to thrombopoietin (TPO) signaling. *Blood* 94 (Suppl.1): 264a, 1999
110. McCarty JM, Melone PD, **Kaushansky K**: IL-11 and TTP plasma mediate differential patterns of thrombopoietin (TPO) induction in cells of endothelial and bone marrow stromal derivation. *Blood* 94 (Suppl. 1): 262a, 1999
111. **Kaushansky K**, Rojnuckarin P, Miyakawa Y, Geddis A, Habib T, Carow CE, Fox N, Drachman JG: Towards a molecular understanding of thrombopoiesis. *Acta Haematol* 103(Suppl. 1): 18, 2000
112. **Kaushansky K**, Rojnuckarin P, Miyakawa Y, Geddis A, Habib T, Carow CE, Fox N, Drachman JG: Towards a molecular understanding of thrombopoiesis. *Acta Haematol* 103(Suppl. 1): 18, 2000
113. Kyriakides TR, Papayannopoulou Th, Rojnuckarin P, **Kaushansky K**, Reidy M, Hankenson K, Bornstein P: Uptake of TSP2 by megakaryocytes: A potential explanation for the bleeding diathesis and platelet abnormality of TSP2-null mice. *Blood* 96 (Suppl. 1): 815a, 2000
114. Holly R, Parrish-Novak J, Nelson A, **Kaushansky K**, Foster D: Cloning of interleukin 21 and IL-21R: A novel cytokine receptor pair involved in NK cell and B-lymphocyte function. *Blood* 96(Suppl. 1): 487a, 2000
115. Geddis A, **Kaushansky K**: Inhibition of PI3K leads to a block in TPO-induced cell cycling at G1/S in both BaF3/Mpl cells and in primary megakaryocytic progenitors. *Blood* 96(Suppl. 1): 539a, 2000
116. Habib T, **Kaushansky K**: Interleukin 21 and IL-2 differentially activate stat3 and stat5 in BaF3 and CTLL cells. *Blood* 96 (Suppl. 1): 237a, 2000
117. Fox N, **Kaushansky K**: Engagement of Integrin $\alpha 4\beta 1$ but not $\alpha 5\beta 1$ Enhances Thrombopoietin (TPO)-induced Megakaryocyte (MK) Growth. *Blood* 98 (Suppl. 1): 292a, 2001

118. **Kaushansky K**, Fox N, Priestley G, Papayannopoulou T. Thrombopoietin (TPO) Expands Hematopoietic Stem Cells (HSC) *in vivo*. Blood 98 (Suppl. 1): 454a, 2001
119. Rojnuckarin P, Fox N, Lin NL, **Kaushansky K**: P selectin interacts with c-Mpl and augments thrombopoietin (TPO) -induced megakaryocyte (MK) differentiation. Blood 98 (Suppl. 1): 797a, 2001
120. Fox N, Lin NL, **Kaushansky K**: Lineage-specific growth factors can compensate for stem and progenitor cell deficiencies at the post-progenitor cell level: An Analysis of Doubly *Tpo* and *G-Csf Receptor* *-/-* Mice. Blood 98 (Suppl. 1): 70a, 2001
121. Habib T, Weinberg KI, **Kaushansky K**: The Interleukin-2 (IL-2) Receptor Common γ Chain (γ c) is a Required Signaling Component of the IL-21 Receptor and Supports IL-21-Induced Cell Proliferation via JAK3.. Blood 98 (Suppl. 1): 818a, 2001
122. Zhao S, Zoller K, Masuko M, Xian X, Rojnuckarin P, **Kaushansky K**, Willerford D, Blau CA. A pivotal role for JAK2 in the self-renewal of primitive hematopoietic cells. Blood 98 (Suppl.1): 78a, 2001
123. Geddis AE, Rosenfeld M, Cheung R, **Kaushansky K**. Thrombopoietin (TPO) induces cell proliferation by several PI3K-dependent pathways: Dissection of the roles of Akt, c-myc, and PKC ζ in megakaryocyte development. Blood 98 (Suppl.1): 287a, 2001
124. Geddis AE, Lin N, Kaushansky K. Endomitotic megakaryocytes (MKs) express the anaphase proteins survivin and AIM-1/STK-1 and they are localized to the spindle and kinetochore. Blood 98 (Suppl.1): 554a, 2001
125. Kirito K, **Kaushansky K**: Thrombopoietin Stimulates HOXB4 Expression in a p38 Dependent Manner: An Explanation for the Favorable Effects of TPO on Hematopoietic Stem Cells? Blood 100 (Suppl. 1): 27a, 2002
126. Kirito K, **Kaushansky K**: Thrombopoietin (TPO) Favorably Affects Hematopoietic Stem Cell (HSC) Expansion by Inducing the Nuclear Translocation of HoxA9, and Its Interaction with Pbx and Meis1. Blood 102 (Suppl. 1): 565a, 2003
127. Kirito K, **Kaushansky K**: Thrombopoietin (TPO) Enhances Autocrine Expression of Vascular Endothelial Growth Factor (VEGF) as a Mechanism of the Favorable Effects of TPO on Hematopoietic Stem Cells. Blood 102 (Suppl. 1): 821a, 2003
128. Geddis AE, Fox NE, **Kaushansky K**: Thrombopoietin (TPO) Promotes Platelet Recovery from a Myelosuppressive Regimen by Mechanisms That Are Independent of p53. Blood 102 (Suppl. 1): 353a, 2003
129. Habib T, **Kaushansky K**: Interleukin-21 Limits STAT5-dependent Pro-mitogenic Signaling in Response to IL-2. Blood 102 (Suppl. 1): 85a, 2003
130. Geddis AE, Fox NE, **Kaushansky K**. The c-Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin (TPO) levels. Blood 104 (Suppl. 1) 211a, 2004
131. Geddis AE, **Kaushansky K**. Aurora-B kinase translocates to the midzone in endomitotic megakaryocytes. Blood 104 (Suppl. 1) 357a, 2004
132. McIntosh BJ, Fox NE, **Kaushansky K**. Factors affecting thrombopoietin production from bone marrow stromal cells. Blood 104 (Suppl. 1) 361a, 2004

133. Kirito K, Fox NE, **Kaushansky K**. Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through HIF-1 α . *Blood* 104 (Suppl. 1) 596a, 2004
134. Nakao T, Geddis AE, Fox NE, **Kaushansky K**. PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27Kip1, *Blood* 106 (Suppl. 1) 62a, 2005
135. Yoshida K, Kirito K, **Kaushansky K**, Komatsu N. Thrombopoietin (TPO) regulates HIF-1 α level through generation of mitochondrial reactive oxygen species (ROS). *Blood* 106 (Suppl. 1) 879a, 2005
136. Geron I, Barroga C, Gotlieb J, Kavalerchek E, Abrahamsson A, Goff D, Cascalano N, Hood J, Soll R, Noronha G, Tefferi A, Weismann IL, **Kaushansky K**, Jamieson CN. Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist. *Blood* 108 (Suppl. 1); 1033a, 2006
137. Hitchcock I, **Kaushansky K**. Thrombopoietin promotes b1 integrin-mediated adhesion in hematopoietic cells via the small GTPase Rap1. *Blood* 108 (Suppl. 1); 405a, 2006
138. Hitchcock I, Fox NE, Sear K, Tiedt R, Skoda R, **Kaushansky K**. Focal Adhesion Kinase in megakaryopoiesis: A study of megakaryocyte-specific *FAK* deletion. *Blood* 108 (Suppl. 1); 109a, 2006
139. Geddis A, Fox NE, Sear K, Tkachenko E, **Kaushansky K**. Endomitotic MKs undergo cortical contraction during anaphase but do not complete furrow ingression. *Blood* 108 (Suppl. 1); 333a, 2006
140. Hitchcock IS, Chen M, King JM, **Kaushansky K**. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor Mpl regulate receptor internalization and degradation. *Blood* 110 (Suppl. 1); 35a, 2007
141. Geron I, Abrahamsson A, Barroga C, Kavalerchik E, Gotlib J, Hood J, Durocher J, Mak CC, Noronha G, Soll R, Tefferi A, **Kaushansky K**, Jamieson C. Selective inhibition of JAK2 driven erythroid differentiation of polycythemia vera progenitors. *Blood* 110 (Suppl. 1); ___a, 2007
142. Barroga C, Pham H, **Kaushansky K**. TPO-induced miR-150 down-regulates c-Myb in primary megakaryocytes and a megakaryocytic cell line. *Blood* 110 (Suppl. 1); ___a, 2007
143. Saur SJ, Geddis AE, **Kaushansky K**, Hitchcock I. Thrombopoietin-mediated ubiquitination and degradation of c-Mpl. *Blood* 112 (Suppl. 1): 2889a, 2008
144. Persico J, Budjehardo I, **Kaushansky K**. The Homodimeric hematopoietic cytokine receptor c-Mpl requires cross phosphorylation in order to signal cell proliferation. *Blood* 112 (Suppl. 1): 3734a, 2008
145. Fox NE, Chen R, Hitchcock I, **Kaushansky K**, Geddis A. Erythropoietin stimulates thrombopoiesis in the absence of c-Mpl signaling. *Blood* 112 (Suppl. 1): 2451a, 2008
146. Jung AS, Kaushansky A, **Kaushansky K**. Functional interaction between c-MPL and tensin2: A novel and potentially important pathway in thrombopoietin mediated signaling. *Blood* 114 (Suppl. 1); abstract 3609, 2009

147. Hitchcock IS, Roh ME, Sangkhae V, Etheridge L, Chen R, Fox NE, **Kaushansky K**. Lineage Restricted JAK2V617F Expression and Its Role in Thrombosis and Hemostasis; The Potential Involvement of Endothelial JAK2V617F in Clotting Abnormalities. *Blood* 118 (Suppl. 1); abstract 1737, 2011
148. Etheridge L, Corbo LM, **Kaushansky K**, Chan E, Hitchcock IS. A Novel Activating JAK2 Mutation, JAK2R564Q, Causes Familial Essential Thrombocytosis (fET) Via Mechanisms Distinct From JAK2V617F. *Blood* 118 (Suppl. 1); abstract 123, 2011
149. **Kaushansky K**. Thrombopoietin: From theory to Reality. Korean Society of Hematology Annual Meeting, 2012
150. Singh M, **Kaushansky K**. Faculty promotions, a reality check: Time to advocate for a career track in quality improvement and patient safety and a Faculty Quality Portfolio. American Association of Medical Colleges Annual Meeting, 2013.
151. Zhan H, Ma Y, **Kaushansky K**. JAK2^{V617F}-mutant megakaryocytes contribute to stem cell expansion in myeloproliferative neoplasms. *Blood* 126 (Suppl. 1); abstract, 2015
152. Lin CHS, **Kaushansky K**, Zhan H. JAK2^{V617F}-mutant vascular niche promotes JAK2^{V617F} clonal expansion in myeloproliferative neoplasms. *Blood* 128 (Suppl. 1) abstract 952, 2016